Search for Press in the web?

Press (36)

Interwin Offer Online Sports Betting Games to Enjoy

www.pressnews.biz
Submitted 20 day(s) ago by interwintrustedcasino

Interwin is offering a various online sports betting game that has gained popularity in a short period. Our sports games are easy to play and can earn a high prize for online games.

White House press office screened questions to Jen Psaki

nypost.com
Submitted 29 day(s) ago by system

​The Biden White House press office has come under fire for reaching out to Capitol reporters to quiz them about the questions they'll ask press secretary Jen Psaki during scheduled briefings, according to a report on Tuesday.​​

Want to Play trusted casino go 918kiss Login ,Xe88 Login at 857bets 2021

www.pressroom.biz
Submitted 33 day(s) ago by trustedcasino

Xe88 Login,918kiss Login,Mega888 Login pc,Angpow Kiss918,918kiss Sign Up,918kiss Jackpot,Kiosk 918kiss Register Agent,918kiss Id Register

The Benefits of a Press Release For Your Brand or Website in Japan

www.topicnews.cn
Submitted 44 day(s) ago by shovelcopper28

If you are considering distributing your press release in Japan and need some help, you have come to the right place! Using the right Japanese press release distribution service is the key to success in any business due to its several benefits. 

Press releases are a popular way for businesses or websites to get immediate exposure for their service or product. This is an effective and affordable method to promote your business and get your message to the targeted audience.

There isn’t much information about why press release distribution is so essential to have inside your business. This article will explore all the advantages of hiring a good press release distribution service and why it’s necessary if you want your website to reach a wider audience.
There are several benefits of press release distribution. Here are 5 of them.

1. All Businesses can Benefit from Press Releases
As you know, content is king, and distribution is queen; no matter what industry you’re in and how big or small your field is, you can benefit from press release distribution. Even if you don’t have that “Oprah story”, you do have stories that can get you coverage in magazines, blogs, trade journals, podcasts, and other publications that cover your industry. Indeed, you can’t get that publicity unless you tell your story.

2. Immediate Exposure to an Established Audience
Press release is a great way to get immediate exposure to your brand or website from a publication that already has an established base of devoted readers and followers.
It's vital to quickly hit the ground as a new website or brand and gain some initial traction to your website and product.
Press releases effectively help you gain that initial traction to your website so people know who you are and what you are offering at the right time.

3. Affordable Cost‍
As a new business owner, it’s essential to keep your advertising and marketing costs in check. The great thing about the press release is that they are beneficial while remaining very inexpensive. The overall cost of a press release is much cheaper than other forms of traditional paid advertising.

4. Potential Sales Increase
On top of helping your brand gain more exposure at an affordable cost, a press release can help you generate more sales. It’s worth mentioning that this is not a guarantee but can indeed happen if your product and brand are positioned accordingly in a niche that aligns with the audience's interests.

5. Major SEO Benefits
Press releases serve as a great way to boost the SEO profile of your website. Press releases published by several media outlets will provide you authority backlinks to your website. Besides, by optimizing your content, you could increase its visibility in search engines and drive organic search engine traffic. So, it’s essential to optimize your SEO content to see positive results from your press release.

As you can see, there are some profound benefits of a press release that can positively impact your brand and business. It’s essential you fully make this decision based on your business's needs and whether or not a press release suits your marketing strategy.

Check out on our exceptional press release services in China, Japan, Korea, Taiwan and find out how they could help you and your brand steal the show in any industry.

Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical drug / therapy products


Submitted 56 day(s) ago by Harry sins

Owing to the ever-increasing number of start-ups that are involved in R&D of novel biologics, there is an enormous opportunity for the CMOs in this domain. It is worth emphasizing that, since 2000, more than 115 new CMOs have been established in order to serve to the growing demand for novel biologics that have specific manufacturing requirements. The contemporary contract services market features a mix of large and small-sized CMOs and is characterized by multiple mergers and acquisitions as stakeholders strive to broaden their respective service portfolios. This has enabled several CMOs to offer end-to-end services, ranging from drug development, including preliminary R&D, preclinical and clinical trials, to commercial scale production and regulatory filings

 

To order this 750+ page report, which features 200+ figures and 250+ tables, please visit this link

 

The USD 13.9 billion (by 2030) financial opportunity within the biopharmaceutical manufacturing market has been analyzed across the following segments:

  • Commonly Outsourced Business Operations
  • Active Pharmaceutical Ingredients (API)
  • Finished Dosage Formulations (FDF)
  • Types of Expression System
  • Mammalian
  • Microbial
  • Others
  • Company Size
  • Small
  • Mid-Sized
  • Large and Very Large
  • Scale of Operation
  • Preclinical
  • Clinical
  • Commercial
  • Key Geographical Region 
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World 

 

The Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030. report features the following companies, which we identified to be key players in this domain:

  • 3P Biopharmaceuticals
  • Abzena
  • Albany Molecular Research
  • BioVectra
  • BioXcellence (Boehringer Ingelheim)
  • Celonic
  • Charles River Laboratories
  • ChemPartner
  • Cobra Biologics
  • CordenPharma
  • Cytovance Biologics
  • GE Healthcare
  • Goodwin Biotechnology
  • Grand River Aseptic Manufacturing
  • IDT Biologika
  • KBI BioPharma
  • Kemwell Biopharma
  • LFB Biomanufacturing
  • Meridian Life Science
  • Patheon
  • Pfizer CentreOne
  • PX'Therapeutics
  • Samsung BioLogics
  • Sanofi, CEPiA
  • Thermo Fisher Scientific
  • Vetter Pharma International

 

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Competitive Landscape

  4. Biopharmaceutical Contract Manufacturing in North America

  5. Biopharmaceutical Contract Manufacturing in Europe

  6. Biopharmaceutical Contract Manufacturing in Asia Pacific And the Rest of The World

  7. Biopharmaceutical Contract Manufacturing in Asia Pacific And the Rest of The World

 

  1. Case Study: Outsourcing of Biosimilars

  2. Case Study: Comparison of Small Molecule and Large Molecule Drugs / Therapies

 

  1. Case Study on In-House Manufacturing

  2. Collaborations

  3. Recent Developments

  4. Capacity Analysis

 

  1. Demand Analysis

 

  1. Market Forecast

 

  1. SWOT Analysis

 

  1. Future of The Biopharmaceutical CMO Market

 

  1. Survey Analysis

 

  1. Interview Transcripts

 

  1. Appendix 1: List of Non-Industry Players

 

  1. Appendix 1: List of Non-Industry Players

 

  1. Appendix 3: List of Companies and Organizations

 

To purchase a copy, please visit https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

 

Contact Details

 

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com  

 

 

The biopharmaceutical contract manufacturing market is projected to grow at an annualized rate of ~8%, till 2030


Submitted 56 day(s) ago by Harry sins

 

 

Roots Analysis has done a detailed study on Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 750+ page report, which features 200+ figures and 250+ tables, please visit this link

 

Key Market Insights

  • Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical drug / therapy products.
  • The market landscape is highly fragmented featuring the presence of both established players and new entrants; majority of biopharmaceutical CMOs are based in the developed geographies.
  • Case study: CMOs focusing on niche biologic markets, primarily novel product candidates for which in-house biomanufacturing expertise is low, are likely to experience significant growth in the coming years.
  • The installed global contract manufacturing capacity, spread across various geographies, is currently estimated to be over 4.5 million liters.
  • The demand for contract manufacturing services is expected to rise across different therapeutic areas; closer inspection of available capacity and expected utilization trend are required to optimize supply parameters.
  • With over 450 deals inked in the past six years, there has been a surge in the partnership activity; majority of the collaborations have been signed for the development and manufacturing of cell therapies and antibodies.
  • In order to cater the increasing demand for biologics, stake holders are actively expanding their existing capabilities; this is evident from the various acquisitions that have recently been reported.
  • We expect the developers to continue to outsource their manufacturing operations in the short to mid-term, resulting in an annualized growth rate of more than 8%.
  • In the long term, the projected opportunity is anticipated to be well distributed across various types of expression systems used for biomanufacturing, scale of operation and size of contract service providers

 

For more information, please visit https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

 

Table of Contents

 

  1. PREFACE

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.      Context and Background

3.2.      An Overview of Biopharmaceuticals

3.3.      Biopharmaceutical Manufacturing

3.3.1.    Types of Expression Systems

3.3.1.1. Bacterial Expression Systems

3.3.1.2. Yeast Expression Systems

3.3.1.3. Fungal Expression Systems

3.3.1.4. Insect Expression Systems

3.3.1.5. Plant Expression Systems

3.3.1.6. Mammalian Expression Systems

 

3.3.2.    Manufacturing Steps

3.3.2.1. Upstream Processing

3.3.2.2. Downstream Processing

 

3.4.      An Overview of Contract Manufacturing

3.5.      Need for Outsourcing in the Biopharmaceutical Industry

3.6.      Commonly Outsourced Operations in the Biopharmaceutical Industry

3.7.      Basic Guidelines for Selecting a CMO Partner

3.8.      Advantages of Outsourcing Manufacturing Services

3.9.      Risks and Challenges Associated with Biopharmaceutical Contract Manufacturing

3.10.     Concluding Remarks

 

  1. COMPETITIVE LANDSCAPE

4.1.      Chapter Overview

4.2.      Biopharmaceuticals Contract Manufacturers: Overall Market Landscape

4.2.1.    Analysis by Size of Employee Base

4.2.2.    Analysis by Location of Headquarters

4.2.3.    Analysis by Year of Establishment

4.2.4.    Analysis by Location of Manufacturing Facilities

4.2.5.    Analysis by Type of Biologics Manufactured

4.2.6.    Analysis by Scale of Operation

4.2.7.    Analysis by Expression Systems

4.2.8.    Analysis by Type of Bioreactor and Modes of Operation

4.2.9.    Analysis by Biomanufacturing Capacity

4.2.10.  Analysis by Packaging Form

4.3.      Concluding Remarks

 

  1. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA

5.1.      Chapter Overview

5.2.      Biopharmaceutical Outsourcing in the US: Regulatory Scenario

5.2.1.    Impact of Current Political Situation

5.3.      Leading Biopharma CMOs in North America

5.3.1.    AMRI (OsoBio)

5.3.1.1. Company Overview

5.3.1.2. Services Portfolio

5.3.1.3. Financial Information

5.3.1.4. Manufacturing Facilities

5.3.1.5. Partnerships

5.3.1.6. Recent Developments

5.3.1.7. Future Outlook

 

5.3.2.    Baxter BioPharma Solutions

5.3.2.1. Company Overview

5.3.2.2. Services Portfolio

5.3.2.3. Financial Information

5.3.2.4. Manufacturing Facilities

5.3.2.5. Partnerships

5.3.2.6. Recent Developments

5.3.2.7. Future Outlook

 

5.3.3.    Catalent Biologics (Catalent Pharma Solutions)

5.3.3.1. Company Overview

5.3.3.2. Services Portfolio

5.3.3.3. Financial Information

5.3.3.4. Manufacturing Facilities

5.3.3.5. Partnerships

5.3.3.6. Recent Developments

5.3.3.7. Future Outlook

 

5.3.4.    Cytovance Biologics

5.3.4.1. Company Overview

5.3.4.2. Services Portfolio

5.3.4.3. Partnerships

5.3.4.4. Recent Developments

5.3.4.5. Future Outlook

 

5.3.5.    Patheon

5.3.5.1. Company Overview

5.3.5.2. Services Portfolio

5.3.5.3. Financial Information

5.3.5.4. Manufacturing Facilities

5.3.5.5. Partnerships

5.3.5.6. Recent Developments

5.3.5.7. Future Outlook

 

5.3.6.    Piramal Pharma Solutions

5.3.6.1. Company Overview

5.3.6.2. Services Portfolio

5.3.6.3. Financial Information

5.3.6.4. Facilities

5.3.6.5. Partnerships

5.3.6.6. Recent Developments

5.3.6.7. Future Outlook

 

  1. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE

6.1.      Chapter Overview

6.2.      Biopharmaceutical Outsourcing in Europe: Regulatory Scenario

6.3.      Leading Biopharmaceutical CMOs in Europe

6.3.1.    3P Biopharmaceuticals

6.3.1.1. Company Overview

6.3.1.2. Services Portfolio

6.3.1.3. Manufacturing Facilities

6.3.1.4. Partnerships

6.3.1.5. Recent Developments

6.3.1.6. Future Outlook

 

6.3.2.    Boehringer Ingelheim BioXcellence™

6.3.2.1. Company Overview

6.3.2.2. Services Portfolio

6.3.2.3. Financial Information

6.3.2.4. Manufacturing Facilities

6.3.2.5. Partnerships

6.3.2.6. Recent Developments

6.3.2.7. Future Outlook

 

6.3.3.    Celonic

6.3.3.1. Company Overview

6.3.3.2. Services Portfolio

6.3.3.3. Manufacturing Facilities

6.3.3.4. Partnerships

6.3.3.5. Recent Developments

6.3.3.6. Future Outlook

 

6.3.4.    FUJIFILM Diosynth Biotechnologies

6.3.4.1. Company Overview

6.3.4.2. Services Portfolio

6.3.4.3. Financial Information

6.3.4.4. Manufacturing Capabilities

6.3.4.5. Partnerships

6.3.4.6. Recent Developments

6.3.4.7. Future Outlook

 

6.3.5.    LFB Group

6.3.5.1. Company Overview

6.3.5.2. Services Portfolio

6.3.5.3. Financial Information

6.3.5.4. Manufacturing Facilities

6.3.5.5. Partnerships

6.3.5.6. Recent Developments

6.3.5.7. Future Outlook

 

6.3.6.    Lonza

6.3.6.1. Company Overview

6.3.6.2. Services Portfolio

6.3.6.3. Financial Information

6.3.6.4. Manufacturing Facilities

6.3.6.5. Partnerships

6.3.6.6. Recent Developments

6.3.6.7. Future Outlook

 

6.3.7.    Menarini Biotech

6.3.7.1. Company Overview

6.3.7.2. Services Portfolio

6.3.7.3. Partnerships

6.3.7.4. Future Outlook

 

6.3.8.    Novasep

6.3.8.1. Company Overview

6.3.8.2. Services Portfolio

6.3.8.3. Financial Information

6.3.8.4. Partnerships

6.3.8.5. Recent Developments

6.3.8.6. Future Outlook

 

6.3.9.    Rentschler BioPharma

6.3.9.1. Company Overview

6.3.9.2. Services Portfolio

6.3.9.3. Manufacturing Facilities

6.3.9.4. Partnerships

6.3.9.5. Recent Developments

6.3.9.6. Future Outlook

 

  1. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA PACIFIC AND THE REST OF THE WORLD

7.1.      Chapter Overview

 

7.2.      Biopharmaceutical Contract Manufacturing in China

7.2.1.    Biopharmaceutical Outsourcing in China: Regulatory Scenario

7.2.2.    Challenges Faced while Outsourcing to China

 

7.3.      Biopharmaceutical CMOs in China

7.3.1.    AutekBio

7.3.1.1. Company Overview

7.3.1.2. Services Portfolio

7.3.1.3. Manufacturing Facilities

7.3.1.4. Future Outlook

 

7.3.2.    WuXi AppTec (WuXi Biologics)

7.3.2.1. Company Overview

7.3.2.2. Services Portfolio

7.3.2.3. Financial Information

7.3.2.4. Manufacturing Facilities

7.3.2.5. Partnerships

7.3.2.6. Recent Developments

7.3.2.7. Future Outlook

 

7.4.      Biopharmaceutical Contract Manufacturing in India

7.4.1.    Biopharmaceutical Outsourcing in India: Regulatory Scenario

7.4.2.    Challenges Faced while Outsourcing to India

 

7.5.      Biopharmaceutical CMOs in India

7.5.1.    Intas Pharmaceuticals

7.5.1.1. Company Overview

7.5.1.2. Services Portfolio

7.5.1.3. Financial Information

7.5.1.4. Manufacturing Facilities

7.5.1.5. Future Outlook

 

7.5.2.    Kemwell Biopharma

7.5.2.1. Company Overview

7.5.2.2. Services Portfolio

7.5.2.3. Manufacturing Facilities

7.5.2.4. Partnerships

7.5.2.5. Recent Developments

7.5.2.6. Future Outlook

 

7.5.3.    Shasun Pharmaceuticals

7.5.3.1. Company Overview

7.5.3.2. Services Portfolio

7.5.3.3. Financial Information

7.5.3.4. Future Outlook

 

7.5.5.    Syngene

7.5.5.1. Company Overview

7.5.5.2. Services Portfolio

7.5.5.3. Financial Information

7.5.5.4. Manufacturing Facilities

7.5.5.5. Partnerships

7.5.5.6. Recent Developments

7.5.5.7. Future Outlook

 

7.6.      Biopharmaceutical Contract Manufacturing in Japan

7.6.1.    Biopharmaceutical Outsourcing in Japan: Regulatory Scenario

 

7.6.      Biopharmaceutical CMOs in Japan

7.6.1.    Asahi Glass

7.6.1.1. Company Overview

7.6.1.2. Services Portfolio

7.6.1.3. Financial Information

7.6.1.4. Manufacturing Facilities

7.6.1.5. Partnerships

7.7.1.6. Recent Developments

7.7.1.7. Future Outlook

 

7.7.      Biopharmaceutical Contract Manufacturing in South Korea

7.7.1.    Biopharmaceutical Outsourcing in South Korea: Regulatory Scenario

 

7.7.      Biopharmaceutical CMOs in South Korea

7.7.1.    DM Bio

7.7.1.1. Company Overview

7.7.1.2. Services Portfolio

7.7.1.3. Manufacturing Facilities

7.7.1.4. Future Outlook

 

7.7.2.    Samsung BioLogics

7.7.2.1. Company Overview

7.7.2.2. Services Portfolio

7.7.2.3. Financial Information

7.7.2.4. Manufacturing Facilities

7.7.2.5. Partnerships

7.7.2.6. Recent Developments

7.7.2.7. Future Outlook

 

7.8.      Biopharmaceutical Contract Manufacturing in Australia

7.8.1.    Biopharmaceutical Outsourcing in Australia: Regulatory Scenario

 

7.8.      Biopharmaceutical CMOs in Australia

7.8.2.    Cell Therapies

7.8.2.1. Company Overview

7.8.2.2. Services Portfolio

7.8.2.3. Manufacturing Facilities

7.8.2.4. Partnerships

7.8.2.5. Recent Developments

7.8.2.6. Future Outlook

 

7.8.3.    Luina Bio

7.8.3.1. Company Overview

7.8.3.2. Services Portfolio

7.8.3.3. Manufacturing Facilities

7.8.3.4. Partnerships

7.8.3.5. Future Outlook

 

  1. NICHE BIOPHARMACEUTICAL SECTORS

8.1.      Chapter Overview

8.2.      Antibody Drug Conjugates

8.2.1.    Introduction

8.2.1.1. Manufacturing Process

8.2.1.2. Key Technologies and Technology Providers

 

8.2.2.    Pipeline Analysis

8.2.2.1. ADC Pipeline: Marketed and Clinical Molecules

8.2.2.2. ADC Pipeline: Preclinical and Discovery Stage Molecules

8.2.2.3. ADC Manufacturing: Key Challenges

 

8.3.      Bispecific Antibodies

8.3.1.    Introduction

8.3.1.1. The Bispecific Advantage

8.3.2.    Pipeline Analysis

8.3.3.    Bispecific Antibody Technology Providers

8.3.4.    Contract Manufacturing Scenario

 

8.4.      Cell Therapies

8.4.1.    Introduction

8.4.2.    Current Market Landscape

8.4.3.    Cell Therapy Manufacturing

8.4.4.    Cell Therapy Manufacturing Models

8.4.4.1. Centralized Manufacturing Model

8.4.4.2. Decentralized Manufacturing Model

 

8.4.5.    Cell Therapy Manufacturing: Key Challenges and Growth Drivers

8.4.6.    Important Factors for Cell Therapy Manufacturing

8.4.6.1. Cell Characterization

8.4.6.2. Cost of Goods

8.4.7.    Contract Manufacturing Scenario

8.4.7.1. Analysis by Type of Cells Manufactured

8.4.7.2. Analysis by Scale of Operation

 

8.5.      Gene Therapy

8.5.1.    Introduction

8.5.2.    Gene Therapy: Pipeline Analysis

8.5.2.1. Analysis by Phase of Development

8.5.2.2. Analysis by Type of Vector

8.5.2.3. Analysis by Therapeutic Area

 

8.5.3.    Contract Manufacturing Market Landscape

8.5.3.1. Analysis by Location

8.5.3.2. Analysis by Type of Viral Vector

8.5.3.3. Analysis by Scale of Production

 

8.6.      Plasmid DNA

8.6.1.    Introduction

8.6.2.    Contract Manufacturing Market Landscape

8.6.3.    Analysis by Location of Manufacturing Facility

8.6.4.    Analysis by Scale of Production

 

  1. CASE STUDY: OUTSOURCING OF BIOSIMILARS

9.1.      Chapter Overview

9.2.      Biosimilars: An Introduction

9.3.      Biosimilars: Development Stages

9.4.      Regulatory Requirements for Licensing of Biosimilars

9.5.      Need for Outsourcing Biosimilar Development and Manufacturing

9.6.      Impact of Biosimilars on the Global Contract Manufacturing Market

9.6.1.    Region-wise Distribution of Biosimilar Development / Manufacturing Activity

9.7.      List of Biosimilars Contract Manufacturing Service Provider

9.8.      Challenges Associated with Biosimilar Outsourcing

 

  1. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULE DRUGS / THERAPIES

10.1.     Chapter Overview

10.2.     Small Molecule and Large Molecule Drugs / Therapies

10.2.1. Comparison of General Characteristics

10.2.2. Comparison of Key Specifications

10.2.3. Comparison of Manufacturing Processes

10.2.4. Comparison of Key Manufacturing Challenges

 

  1. CASE STUDY ON IN-HOUSE MANUFACTURING

11.1.     Chapter Overview

11.2.     In-House Manufacturing

11.2.1. Benefits Associated with In-House Manufacturing

11.2.2. Risks Associated with In-House Manufacturing

 

11.3.     Outsourcing in the Biomanufacturing Industry

11.3.1. Types of Outsourcing Partners

 

11.4.     Manufacturing Approaches Used for Approved Biologics (2016-2018)

11.4.1. Approved Biologics: Distribution by Size of Type of Manufacturing Approach

11.4.2. Approved Biologics: Distribution by Size of Developer and Type of Biologic

 

11.5.     Choosing the Right Strategy: In-House Manufacturing versus Outsourcing

 

  1. COLLABORATIONS

12.1.     Chapter Overview

12.2.     Partnership Models

12.3.     Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations

12.3.1.  Analysis by Year of Partnerships

12.3.2.  Analysis by Type of Partnerships

12.3.2.1. Year-Wise Trend of Product-based Agreements

12.3.2.2. Year-Wise Trend of Process-based Agreements

12.3.2.3. Year-Wise Trend of Licensing Agreements

12.3.2.4. Year-Wise Trend of Co-service Agreements / Ventures

12.3.2.5. Year-Wise Trend of R&D Agreements

12.3.2.6. Year-Wise Trend of Out-sourcing Services Agreements

 

12.3.3. Analysis by Focus Area

12.3.4. Analysis by Type of Biologics

12.3.4.1. Analysis by Type of Biologic and Type of Partnership Model

12.3.4.2. Analysis of Cell Therapy-related Deals by Year and Type of Partnership Model

12.3.4.3. Analysis of Monoclonal Antibody-related Deals by Year and Type of Partnership Model

12.3.4.4. Analysis of Vaccine-related Deals by Year and Type of Partnership Model

12.3.4.5. Analysis of Protein-related Deals by Year and Type of Partnership Model

12.3.4.6. Analysis of Antibody Drug Deals by Year and Type of Partnership Model

12.3.4.7. Analysis of Vector-related Deals by Year and Type of Partnership Model

12.3.4.8. Analysis of Gene Therapy-related Deals by Year and Type of Partnership Model

12.3.4.9. Analysis of Biosimilar-related Deals by Year and Type of Partnership Model

12.3.4.10. Analysis of Other Biologic-related Deals by Type of Partnership Model

12.3.4.11. Analysis by Type of Biologics and Geography

 

12.3.5.  Analysis by Therapeutic Area

12.3.6.  Analysis of Most Active Players by Number of Partnerships

12.3.7.  Regional Analysis

12.3.7.1. Intercontinental and Intracontinental Agreements

 

12.4.     Mergers and Acquisitions

12.4.1.  Acquisitions Models

12.4.2.  Biopharmaceutical Contract Manufacturing: Mergers and Acquisitions

12.4.3.  Cumulative Year-wise Trend

12.4.4.  Analysis by Type of Acquisition

12.4.5.  Geographical Activity

12.4.5.1. Mergers and Acquisitions: Continent-wise Distribution

12.4.5.2. Mergers and Acquisitions: Country-wise Distribution

12.4.5.3. Mergers and Acquisitions: Intercontinental and Intracontinental Deals

 

12.4.6.  Most Active Acquirers: Analysis by Number of Acquisitions

12.4.7   Mergers and Acquisitions: Distribution by Key Value Drivers and Type of Biologics

12.4.7.1. Mergers and Acquisitions: Analysis by Key Value Drivers

12.4.7.2. Mergers and Acquisitions: Analysis by Key Value Drivers and Year of Acquisition

12.4.7.3. Mergers and Acquisitions: Analysis by Type of Biologics

12.4.7.4. Mergers and Acquisitions: Analysis by Type of Biologics and Key Value Drivers

12.5.     Key Acquisitions: Deal Multiples

 

  1. RECENT DEVELOPMENTS

13.1.     Chapter Overview

13.2.     Biopharma Contract Manufacturing Market: Facility Expansions

13.2.1.  Cumulative Year-wise Distribution

13.2.2.  Analysis by Purpose of Facility Expansion

13.2.3.  Analysis by Type of Biologics

13.2.4.  Analysis by Type of Biologics and Purpose of Expansion

13.2.5.  Analysis by Location of Manufacturing Facility

13.2.6.  Regional Analysis

13.2.7. Most Active Players: Analysis by Number of Recent Expansions

13.2.8. Analysis by Headquarters and Purpose

13.2.9. Facility Expansions: Pre-2015 and Post-2015

13.3.     Biopharmaceutical Contract Manufacturing Market: Funding Instances

13.4.     Technological Advancements

13.4.1. Single Use Technology

13.4.2.  Process Analytical Technology (PAT)

13.4.3. Continuous Processing

13.4.3.  Quality by Design in Bioprocessing

 

 

13.3.     Biopharmaceutical Contract Manufacturing Market: Funding Instances

13.4.     Technological Advancements

13.4.1.  Single Use Technology

13.4.2.  Process Analytical Technology

13.4.3.  Continuous Processing

13.4.4.  Quality by Design in Bioprocessing

 

  1. CAPACITY ANALYSIS

14.1.     Chapter Overview

14.2.     Assumptions and Methodology

14.3.     Biopharmaceutical Contract Manufacturers: Global Production Capacity

14.3.1.  Analysis by Size of the CMO

14.3.2. Analysis by Expression Systems

14.3.3.  Analysis by Scale of Operation

14.3.4. Analysis by Region

14.3.4.1. Capacity Analysis: North America

14.3.4.2. Capacity Analysis: Europe

14.3.4.3. Capacity Analysis: Asia and Middle East

14.4.     Emerging Biologics: Capacity Analysis

14.4.1.  ADC Manufacturing Installed Global Capacity: Regional Distribution

14.5.     Cell Therapy Manufacturing Capacity: Regional Distribution

14.6.     Viral Vectors Installed Manufacturer Capacity: Distribution by Location of Manufacturing Facility

14.7.     Concluding Remarks

 

  1. DEMAND ANALYSIS

15.1.     Chapter Overview

15.2.     Key Assumptions and Methodology

15.3.     Overall Annual Demand for Biopharmaceutical Market, 2019-2024

15.3.1. Analysis by Therapeutic Area

 

15.4.     Relationship Between Annual Demand and Capacity

15.5.     Demand for Emerging Novel Biologics

15.5.1. ADCs: Overall Annual Demand

15.5.1. ADCs: Demand and Supply Analysis

 

  1. MARKET FORECAST

16.1.     Chapter Overview

16.2.     Forecast Methodology and Key Assumptions

 

16.3.     Overall Biopharmaceutical Contract Manufacturing Market, 2019-2030

16.3.1. Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2019-2030

16.3.2. Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2019-2030

 

16.4.     Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Expression Systems Used

16.5.     Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation

16.6.     Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Size of Manufacturers

 

16.7.     Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Geography

16.7.1.  Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030

16.7.1.1. Biopharmaceutical Contract Manufacturing Market in the US, 2019-2030

16.7.1.2. Biopharmaceutical Contract Manufacturing Market in Canada, 2019-2030

16.7.1.3. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Mammalian Cell-based Operations

16.7.1.4. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Microbial Cell-based Operations

16.7.1.5. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Other Expression System-based Operations

16.7.1.6. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Preclinical / Clinical Scale Operations

16.7.1.7. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Commercial Scale Operations

16.7.1.8. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Small-sized Companies

16.7.1.9. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Mid-sized Companies

16.7.1.10. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Large / Very Large Companies

 

16.7.2.  Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030

16.7.2.1. Biopharmaceutical Contract Manufacturing Market in Italy, 2019-2030

16.7.2.2. Biopharmaceutical Contract Manufacturing Market in Germany, 2019-2030

16.7.2.3. Biopharmaceutical Contract Manufacturing Market in France, 2019-2030

16.7.2.4. Biopharmaceutical Contract Manufacturing Market in Spain, 2019-2030

16.7.2.5. Biopharmaceutical Contract Manufacturing Market in the UK, 2019-2030

16.7.2.6. Biopharmaceutical Contract Manufacturing Market in Rest of Europe, 2019-2030

 

16.7.2.7. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Mammalian Cell-based Operations

16.7.2.8. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Microbial Cell-based Operations

16.7.2.9. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Other Expression System-based Operations

 

16.7.2.10. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Preclinical / Clinical Operations

16.7.2.11. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Commercial Operations

16.7.2.12. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Small-sized Companies

16.7.2.13. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Mid-sized Companies

16.7.2.14. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Large / Very Large Companies

 

16.7.3.  Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030

16.7.3.1. Biopharmaceutical Contract Manufacturing Market in China, 2019-2030

16.7.3.2. Biopharmaceutical Contract Manufacturing Market in India, 2019-2030

16.7.3.3. Biopharmaceutical Contract Manufacturing Market in South Korea, 2019-2030

16.7.3.4. Biopharmaceutical Contract Manufacturing Market in Japan, 2019-2030

16.7.3.5. Biopharmaceutical Contract Manufacturing Market in Australia, 2019-2030

16.7.3.6. Biopharmaceutical Contract Manufacturing Market in Rest of Asia and Other Regions, 2019-2030

 

16.7.3.7. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Mammalian Cell-based Operations

16.7.3.8. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Microbial Cell-based Operations

16.7.3.9. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Other Expression System-based Operations

 

16.7.3.10. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Preclinical / Clinical Operations

16.7.3.11. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Commercial Scale Operations

 

16.7.3.12. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Small-sized Companies

16.7.3.13. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Mid-sized Companies

16.7.3.14. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Large / Very Large Companies

16.7.4   Overall Biopharmaceutical Contract Manufacturing, 2019-2030: Share by Others Segment

 

  1. SWOT ANALYSIS

17.1      Chapter Overview

17.2.     Strengths

17.3.     Weaknesses

17.4.     Opportunities

17.5.     Threats

17.6.     Comparison of Swot Factors

17.7.     Concluding Remarks

 

  1. FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET

18.1.     Chapter Overview

18.2.     Outsourcing Activities to Witness Significant Growth in the Coming Years

18.3.     Shift from One-time Contracts to Strategic Partnerships

18.4.     Integration / Adoption of New and Innovative Technologies

18.4.1. Single use Bioreactors

18.4.2. Novel Bioprocess Techniques

18.4.3. Bioprocess Automation

 

18.5.     Focus on Niche Therapeutic Areas

18.6.     Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment

18.7.     Capability and Expertise Expansions by CMOs to become One Stop Shops

18.8.     Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities

18.9.     Increase in Financial Inflow and Outsourcing Budgets

18.10.   The Need for Humanized Products to Drive the Growth of Mammalian Expression Technologies

 

18.11.   Challenges Faced by both Sponsors and Service Providers

18.11.1. Concerns related to Single Use Systems

18.11.2. Issues Related to Capacity Fluctuations

 

18.12.   Concluding Remarks

 

  1. SURVEY ANALYSIS

19.1.     Chapter Overview

19.1.1. Overview of Respondents

19.1.2. Designation of Respondents

 

19.2.     Biologics Manufacturing Expertise

19.3.     Scale of Manufacturing

19.4.     Location of Production Facilities

19.5.     Types of Expression Systems Used

19.6.     Types of Bioreactors

19.7.     Modes of Operation of Bioreactors

 

  1. INTERVIEW TRANSCRIPTS

20.1.     Chapter Overview

20.2.     Astrid Brammer, Senior Manager Business Development, Richter-Helm

20.3.     Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie

20.4.     Christian Bailly, Director of CDMO, Pierre Fabre

20.5.     Claire Otjes, Assistant Marketing Manager, Batavia Biosciences

20.6.     David C Cunningham, Director Corporate Development, Goodwin Biotechnology

20.7.     Dietmar Katinger, Chief Executive Officer, Polymun Scientific

20.8.     Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma

20.9.     Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences

20.10.   Kevin Daley, Director Pharmaceuticals, Novasep

20.11.   Mark Wright, Site Head, Grangemouth, Piramal Healthcare

20.12.   Nicolas Grandchamp, R&D Leader, GEG Tech

20.13.   Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals

20.14.   Sebastian Schuck, Head of Business Development, Wacker Biotech

20.15.   Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies

20.16.   Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, Plasmid Factory

20.17.  Tim Oldham, Chief Executive Officer, Cell Therapies

 

  1. APPENDIX 1: LIST OF NON-INDUSTRY PLAYERS

 

  1. APPENDIX 2: TABULATED DATA

 

  1. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

 

 

Contact Details

 

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

Over 115 companies located in various regions across the globe claim to provide contract fill / finish services for various types of biopharmaceutical drug / therapy products, claims Roots Analysis


Submitted 56 day(s) ago by Harry sins

Despite the fact that biopharmaceuticals offer significant profit margins, innovator companies are plagued by high costs of development, complex production protocols and special procedures and equipment for fill / finish operations. Consequently, a number of drug manufacturers have demonstrated a preference for outsourcing fill / finish operations of such products.

 

To order this 480+ page report, which features 350+ figures and 260+ tables, please visit this link

 

The USD 4.2 billion (by 2030) financial opportunity within the biologics fill / finish services market has been analyzed across the following segments:

  • Types of Primary Packaging Containers
  • Ampoules
  • Cartridges
  • Syringes
  • Vials

 

  • Types of Biologics
  • Peptides / proteins
  • Antibodies
  • Vaccines
  • Cell therapies
  • Gene therapies
  • Viral products
  • Oligonucleotides
  • Others

 

  • Company Size
  • Small-sized
  • Mid-sized
  • Large / very large

 

  • Scale of Operation
  • Preclinical
  • Clinical
  • Commercial

 

  • Key Therapeutic Areas
  • Cancer
  • Infectious diseases
  • Autoimmune diseases
  • Cardiovascular diseases
  • Other indications

 

  • Key Geographical Regions
  • North America (US, Canada)
  • Europe (UK, France, Germany, Italy, Spain and rest of the Europe)
  • Asia-Pacific (Japan, China, South Korea, India and Australia)

 

The Biologics Fill / Finish Services Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • Advanced BioScience Laboratories (ABL)
  • Albany Molecular Research (AMRI)
  • Biocon
  • BioPharma Solutions
  • BioReliance
  • Boehringer Ingelheim BioXcellence
  • ChemPartner
  • Emergent BioSolutions
  • IDT Biologika
  • Lonza
  • LuinaBio
  • Mycenax Biotech
  • Patheon
  • Recipharm
  • Vetter Pharma
  • WuXi Biologics

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Competitive Landscape

  4. Company Competitiveness Analysis

  5. Biologics Fill / Finish Service Providers in North America: Company Profiles

  6. Biologics Fill / Finish Service Providers in Europe: Company Profiles

  7. Biologics Fill / Finish Service Providers in Asia-Pacific: Company Profiles

  8. Partnerships and Collaborations

  9. Recent Expansions

  10. Capacity Analysis

  11. Demand Analysis

  12. Biologics Manufacturing and Fill / Finish: Key Performance Indicator Analysis

  13. Market Sizing and Opportunity Analysis

 

  1. Future Growth Opportunities

 

  1. Case Study: Robotic Systems in Fill / Finish Operations

 

  1. Case Study: Ready-to-Use Packaging Components in Aseptic Fill / Finish Operations

 

  1. Conclusion

 

  1. Interview Transcripts

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/biologics-fill--finish-services-market-2019-2030/256.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com  

 

 

The contract fill / finish services market for biologics market is projected to grow at an annualized rate of ~10%, till 2030


Submitted 56 day(s) ago by Harry sins

Roots Analysis has done a detailed study on Biologics Fill / Finish Services Market, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 480+ page report, which features 237 figures and 267 tables, please visit this link

 

Key Market Insights

  • Over 115 companies located in various regions across the globe claim to provide contract fill / finish services for various types of biopharmaceutical drug / therapy products
  • The market landscape features a mix of both established players and new entrants; multiple biologics fill / finish service providers based in developed geographies have already adopted advanced fill / finish technologies
  • Vials represent the most prominent form of packaging used for biopharmaceutical interventions; with increasing demand for self-administration devices, syringes have also garnered significant attention
  • In fact, to acquire competencies across the value chain, stakeholders have actively invested in expanding their existing infrastructure and capabilities to cater to the evolving needs of both indigenous and international clients
  • Over the past six years, the fill / finish services domain has also witnessed significant partnership activity, with companies building strategic business relationships to consolidate their positions in the market
  • The outcome of consolidation is evident from our proprietary competitiveness analysis, based on several relevant parameters highlighting service and supplier strengths
  • Presently, the installed global contract fill / finish capacity, across various geographies, is estimated to be over 17 million units (in term of packaging containers)
  • The demand for contract fill / finish services for biologics is expected to increase in the coming years; it is likely that stakeholders will have to expand their respective capacities to ensure consistent supply
  • We expect biopharmaceutical developers to continue to outsource their fill / finish operations in the short to mid-term, resulting in an annualized growth rate of more than 10%
  • In the long-term, the projected opportunity is anticipated to be well distributed across various types of primary packaging, biological interventions and target disease indications

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/biologics-fill--finish-services-market-2019-2030/256.html

 

Table of Contents

 

  1. PREFACE

1.1.           Scope of the Report

1.2.           Research Methodology

1.3.           Chapter Outlines

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.           Chapter Overview

3.2.           Introduction to Biologics

3.3.           Need for Outsourcing Biologics-related Operations

3.4.           Introduction to Contract Manufacturing 

3.5.           Commonly Outsourced Operations in the Biopharmaceutical Industry

3.5.1.        Biologics Fill / Finish Operations

3.6.           Basic Guidelines for Selecting a Fill / Finish Service Provider

3.7.           Advantages of Outsourcing Fill / Finish Services

3.8.           Risks and Challenges of Outsourcing Fill / Finish Operations

 

  1. COMPETITIVE LANDSCAPE

4.1.           Chapter Overview 

4.2.           Biologics Fill / Finish Service Providers: Overall Market Landscape

4.2.1.        Analysis by Year of Establishment 

4.2.2.        Analysis by Company Size

4.2.3.        Analysis by Location of Headquarters 

4.2.4.        Analysis by Location of Fill / Finish Facilities 

4.2.5.        Analysis by Type of Packaging

4.2.6.        Analysis by Additional Services Offered

4.2.7.        Analysis by Scale of Operation

4.2.8.        Analysis by Type of Biologics Filled

 

  1. COMPANY COMPETITIVENESS ANALYSIS

5.1.           Chapter Overview

5.2.           Methodology

5.3.           Assumptions and Key Input Parameters

 

5.4.           Competitiveness Analysis: Biologics Fill / Finish Service Providers in North America

5.4.1.        Companies Offering Fill / Finish Services for Ampoules

5.4.2.        Companies Offering Fill / Finish Services for Cartridges

5.4.3.        Companies Offering Fill / Finish Services for Syringes

5.4.4.        Companies Offering Fill / Finish Services for Vials

 

5.5.           Competitiveness Analysis: Fill / Finish Service Providers in Europe

5.5.1.        Companies Offering Fill / Finish Services for Ampoules

5.5.2.        Companies Offering Fill / Finish Services for Cartridges

5.5.3.        Companies Offering Fill / Finish Services for Syringes

5.5.4.        Companies Offering Fill / Finish Services for Vials

 

5.6.           Competitiveness Analysis: Fill / Finish Service Providers of Asia-Pacific

5.6.1.        Companies Offering Fill / Finish Services for Ampoules

5.6.2.        Companies Offering Fill / Finish Services for Cartridges

5.6.3.        Companies Offering Fill / Finish Services for Syringes

5.6.4.        Companies Offering Fill / Finish Services for Vials

 

  1. BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN NORTH AMERICA: COMPANY PROFILES

6.1.           Chapter Overview

6.2.           Advanced BioScience Laboratories (ABL)

6.2.1.        Company Overview

6.2.2.        Service Portfolio

6.2.3.        Recent Developments

6.2.4.        Future Outlook

                

6.3.           Albany Molecular Research (AMRI)

6.3.1.        Company Overview

6.3.2.        Service Portfolio

6.3.3.        Financial Information

6.3.4.        Recent Developments

6.3.5.        Future Outlook

                

6.4.           BioPharma Solutions

6.4.1.        Company Overview

6.4.2.        Service Portfolio

6.4.3.        Financial Information

6.4.4.        Recent Developments

6.4.5.        Future Outlook

                

6.5.           BioReliance

6.5.1.        Company Overview

6.5.2.        Service Portfolio

6.5.3.        Financial Information

6.5.4.        Recent Developments

6.5.5.        Future Outlook

                

6.6.           Emergent BioSolutions

6.6.1.        Company Overview

6.6.2.        Service Portfolio

6.6.3.        Financial Information

6.6.4.        Recent Developments

6.6.5.        Future Outlook

                

6.7.           Patheon

6.7.1.        Company Overview

6.7.2.        Services Portfolio

6.7.3.        Financial Information

6.7.4.        Recent Developments

6.7.5.        Future Outlook

 

  1. BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN EUROPE: COMPANY PROFILES

7.1.           Chapter Overview

7.2.           Boehringer Ingelheim BioXcellence

7.2.1.        Company Overview

7.2.2.        Service Portfolio

7.2.3.        Financial Information

7.2.4.        Recent Developments

7.2.5.        Future Outlook

                

7.3.           IDT Biologika

7.3.1.        Company Overview

7.3.2.        Service Portfolio

7.3.3.        Recent Developments

7.3.4.        Future Outlook

                

7.4.           Lonza

7.4.1.        Company Overview

7.4.2.        Service Portfolio

7.4.3.        Financial Information

7.4.4.        Recent Developments

7.4.5.        Future Outlook

                

7.5.           Recipharm

7.5.1.        Company Overview

7.5.2.        Service Portfolio

7.5.3.        Financial Information

7.5.3.        Recent Developments

7.5.4.        Future Outlook

                

7.6.           Vetter Pharma

7.6.1.        Company Overview

7.6.2.        Service Portfolio

7.6.3.        Recent Developments

7.6.4.        Future Outlook

 

  1. BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN ASIA-PACIFIC: COMPANY PROFILES

8.1.           Chapter Overview

8.2.           Biocon

8.2.1.        Company Overview

8.2.2.        Service Portfolio

8.2.3.        Financial Information

8.2.4.        Recent Developments

8.2.5.        Future Outlook

                

8.3.           ChemPartner

8.3.1.        Company Overview

8.3.2.        Service Portfolio

8.3.3.        Recent Developments

8.3.4.        Future Outlook

                

8.4.           LuinaBio

8.4.1.        Company Overview

8.4.2.        Service Portfolio

8.4.3.        Recent Developments

8.4.4.        Future Outlook

                

8.5.           Mycenax Biotech

8.5.1.        Company Overview

8.5.2.        Service Portfolio

8.5.3.        Financial Information

8.5.3.        Recent Developments

8.5.4.        Future Outlook

                

8.6.           Wuxi Biologics

8.6.1.        Company Overview

8.6.2.        Service Portfolio

8.6.3.        Financial Information

8.6.4.        Recent Developments

8.6.4.        Future Outlook

 

  1. PARTNERSHIPS AND COLLABORATIONS

9.1.           Chapter Overview

9.2.           Partnership Models

9.3.           Biologics Fill / Finish Service Providers: List of Partnerships and Collaborations

9.3.1.        Analysis by Year of Partnership

9.3.2.        Analysis by Type of Partnership

9.3.3.        Analysis by Type of Service

9.3.4.        Analysis by Scale of Operation

9.3.5.        Analysis by Type of Biologic

9.3.6.        Analysis by Geographical Location

9.3.7.        Most Active Players: Analysis by Number of Partnerships

9.3.8.        Service Alliances and Supply Agreements: Analysis by Type of Service

9.3.9.        Acquisitions and Mergers: Analysis by Type of Service

 

  1. RECENT EXPANSIONS

10.1.         Chapter Overview

10.2.         Biologics Fill / Finish Service Providers: Recent Expansions

10.2.1.      Analysis by Year of Expansion

10.2.2.      Analysis by Type of Expansion

10.2.3.      Analysis by Type of Packaging

10.2.4.      Analysis by Type of Service

10.2.5.      Analysis by Type of Biologic

10.2.6.      Analysis by Type of Biologic and Scale of Operation

10.2.7.      Analysis by Geographical Location

10.2.8.      Most Active Players: Analysis by Type of Service and Type of Biologic

10.2.9.      Expansions in North America: Analysis by Type of Service and Type of

                  Biologic

10.2.10.     Expansions in Europe: Analysis by Type of Service and Type of Biologic

10.2.11.     Expansions in Asia-Pacific: Analysis by Type of Service and Type of Biologic

 

  1. CAPACITY ANALYSIS

11.1.         Chapter Overview

11.2.         Assumptions and Methodology

11.3.         Global Installed Fill / Finish Capacity (by Number of Units)

11.3.1.      Analysis by Type of Packaging

11.3.2.      Analysis by Size of Manufacturer

11.3.3.      Analysis by Scale of Operation

11.3.4.      Analysis by Location of Headquarters

11.3.5.      Analysis by Location of Fill / Finish Facilities

 

11.4.         Global Installed Fill / Finish Capacity (by Volume)

11.4.1.      Analysis by Type of Packaging

11.4.2.      Analysis by Size of Manufacturer

11.4.3.      Analysis by Scale of Operation

11.4.4.      Analysis by Location of Headquarters

11.4.5.      Analysis by Location of Fill / Finish Facilities

 

11.5.         Global Installed Fill / Finish Capacity for Ampoules (by Number of Units)

11.5.1       Analysis by Size of Manufacturer

11.5.2       Analysis by Scale of Operation

11.5.3.      Analysis by Location of Headquarters

11.5.4       Analysis by Location of Fill / Finish Facilities

                

11.6.         Global Installed Fill / Finish Capacity for Ampoules (by Volume)

11.6.1.      Analysis by Size of Manufacturer

11.6.2.      Analysis by Scale of Operation

11.6.3.      Analysis by Location of Headquarters

11.6.4.      Analysis by Location of Fill / Finish Facilities

                

11.7.         Global Installed Fill / Finish Capacity for Cartridges (by Number of Units)

11.7.1.      Analysis by Size of Manufacturer

11.7.2.      Analysis by Scale of Operation

11.7.3.      Analysis by Location of Headquarters

11.7.4.      Analysis by Location of Fill / Finish Facilities

                

11.8.         Global Installed Fill / Finish Capacity for Cartridges (by Volume)

11.8.1.      Analysis by Size of Manufacturer

11.8.2.      Analysis by Scale of Operation

11.8.3.      Analysis by Location of Headquarters

11.8.4.      Analysis by Location of Fill / Finish Facilities

                

11.9.         Global Installed Fill / Finish Capacity for Syringes (by Number of Units)

11.9.1       Analysis by Size of Manufacturer

11.9.2       Analysis by Scale of Operation

11.9.3.      Analysis by Location of Headquarters

11.9.4       Analysis by Location of Fill / Finish Facilities

                

11.10.       Global Installed Fill / Finish Capacity for Syringes (by Volume)

11.10.1.     Analysis by Size of Manufacturer

11.10.2.     Analysis by Scale of Operation

11.10.3.     Analysis by Location of Headquarters

11.10.4.     Analysis by Location of Fill / Finish Facilities

                

11.11.       Global Installed Fill / Finish Capacity for Vials (by Number of Units)

11.11.1      Analysis by Size of Manufacturer

11.11.2      Analysis by Scale of Operation

11.11.3.     Analysis by Location of Headquarters

11.11.4.     Analysis by Location of Fill / Finish Facilities

                

11.12.       Global Installed Fill / Finish Capacity for Vials (by Volume)

11.12.1.     Analysis by Size of Manufacturer

11.12.2.     Analysis by Scale of Operation

11.12.3.     Analysis by Location of Headquarters

11.12.4.     Analysis by Location of Fill / Finish Facilities

 

11.13.       Conclusion

 

  1. DEMAND ANALYSIS

12.1.         Chapter Overview

12.2.         Assumptions and Methodology

12.3.         Global Demand for Biologics Fill / Finish Services

12.3.1.      Analysis by Type of Packaging

12.3.2.      Analysis by Type of Biologic

12.3.3.      Analysis by Therapeutic Area

12.3.4.      Analysis by Geographical Location

 

12.4.         Demand and Supply Analysis

  1. BIOLOGICS MANUFACTURING AND FILL / FINISH: KEY PERFORMANCE INDICATORS

13.1.         Chapter Overview

13.2.         Biologics Manufacturing and Fill / Finish: Types of Key Performance Indicators

13.2.1.      Financial Indicators

13.2.1.1.    Big Pharma Perspective

13.2.1.2.    Contract Manufacturers’ Perspective

 

 

13.2.2.      Process and Capability Indicators

13.2.2.1.    Big Pharma Perspective

13.2.2.2.    Contract Manufacturers’ Perspective

 

13.2.3.      Market Reputation Indicators

13.2.3.1.    Big Pharma Perspective

13.2.3.2.    Contract Manufacturers’ Perspective

 

13.2.4.      Other Important Performance Indicators

13.3.5.      Conclusion

 

  1. MARKET SIZING AND OPPORTUNITY ANALYSIS

14.1.         Chapter Overview

14.2.         Forecast Methodology

14.3.         Overall Biologics Fill / Finish Services Market, 2019-2030

14.3.1.      Biologics Fill / Finish Services Market, 2019-2030: Distribution by Type of Packaging

14.3.2.      Biologics Fill / Finish Services Market, 2019-2030: Distribution by Scale of Operation

14.3.3.      Biologics Fill / Finish Services Market, 2019-2030: Distribution by Type of Biologic

14.3.4.      Biologics Fill / Finish Services Market, 2019-2030: Distribution by Therapeutic Area

14.3.5.      Biologics Fill / Finish Services Market, 2019-2030: Distribution by Geographical Region

14.3.5.1     Biologics Fill / Finish Services Market in North America, 2019-2030: Distribution by Countries

14.3.5.2.    Biologics Fill / Finish Services Market in North America, 2019-2030: Distribution by Type of Packaging

14.3.5.3.    Biologics Fill / Finish Services Market in North America, 2019-2030: Distribution by Scale of Operation

14.3.5.4.    Biologics Fill / Finish Services Market in North America, 2019-2030: Distribution by Type of Biologic

14.3.5.5.    Biologics Fill / Finish Services Market in North America, 2019-2030: Distribution by Therapeutic Area

14.3.5.6.    Biologics Fill / Finish Services Market in Europe, 2019-2030: Distribution by Countries

14.3.5.7.    Biologics Fill / Finish Services Market in Europe, 2019-2030: Distribution by Type of Packaging

14.3.5.8.    Biologics Fill / Finish Services Market in Europe, 2019-2030: Distribution by Scale of Operation

14.3.5.9.    Biologics Fill / Finish Services Market in Europe, 2019-2030: Distribution by Type of Biologic

14.3.5.10.  Biologics Fill / Finish Services Market in Europe, 2019-2030: Distribution by Therapeutic Area

14.3.5.11.  Biologics Fill / Finish Services Market in Asia Pacific, 2019-2030: Distribution by Countries

14.3.5.12.  Biologics Fill / Finish Services Market in Asia Pacific, 2019-2030: Distribution by Type of Packaging

14.3.5.13. Biologics Fill / Finish Services Market in Asia Pacific, 2019-2030: Distribution by Scale of Operation

14.3.5.14.  Biologics Fill / Finish Services Market in Asia Pacific, 2019-2030: Distribution by Type of Biologic

14.3.5.15.  Biologics Fill / Finish Services Market in Asia Pacific, 2019-2030: Distribution by Therapeutic Area

 

14.4.         Biologics Fill / Finish Services Market for Ampoules, 2019-2030

14.4.2.      Biologics Fill / Finish Services Market for Ampoules, 2019-2030: Distribution by Scale of Operation

14.4.2.      Biologics Fill / Finish Services Market for Ampoules, 2019-2030: Distribution by Type of Biologic

14.4.3.      Biologics Fill / Finish Services Market for Ampoules, 2019-2030: Distribution by Therapeutic Area

14.4.4.      Biologics Fill / Finish Services Market for Ampoules, 2019-2030: Distribution by Geographical Region

14.4.4.1.    Biologics Fill / Finish Services Market for Ampoules in North America, 2019-2030: Distribution by Scale of Operation

14.4.4.2.    Biologics Fill / Finish Services Market for Ampoules in North America, 2019-2030: Distribution by Type of Biologic

14.4.4.3.    Biologics Fill / Finish Services Market for Ampoules in North America, 2019-2030: Distribution by Therapeutic Area

14.4.4.4.    Biologics Fill / Finish Services Market for Ampoules in Europe, 2019-2030: Distribution by Scale of Operation

14.4.4.5.    Biologics Fill / Finish Services Market for Ampoules in Europe, 2019-2030: Distribution by Type of Biologic

14.4.4.6.    Biologics Fill / Finish Services Market for Ampoules in Europe, 2019-2030: Distribution by Therapeutic Area

14.4.4.7.    Biologics Fill / Finish Services Market for Ampoules in Asia Pacific, 2019-2030: Distribution by Scale of Operation

14.4.4.8.    Biologics Fill / Finish Services Market for Ampoules in Asia Pacific, 2019-2030: Distribution by Type of Biologic

14.4.4.9.    Biologics Fill / Finish Services Market for Ampoules in Asia Pacific, 2019-2030: Distribution by Therapeutic Area

                

14.5.         Biologics Fill / Finish Services Market for Cartridges, 2019-2030

14.5.1.      Biologics Fill / Finish Services Market for Cartridges, 2019-2030: Distribution by Scale of Operation

14.5.2.      Biologics Fill / Finish Services Market for Cartridges, 2019-2030: Distribution by Type of Biologic

14.5.3.      Biologics Fill / Finish Services Market for Cartridges, 2019-2030: Distribution by Therapeutic Area

14.5.4.      Biologics Fill / Finish Services Market for Cartridges, 2019-2030: Distribution by Geographical Region

14.5.4.1.    Biologics Fill / Finish Services Market for Cartridges in North America, 2019-2030: Distribution by Scale of Operation

14.5.4.2.    Biologics Fill / Finish Services Market for Cartridges in North America, 2019-2030: Distribution by Type of Biologic

14.5.4.3.    Biologics Fill / Finish Services Market for Cartridges in North America, 2019-2030: Distribution by Therapeutic Area

14.5.4.4.    Biologics Fill / Finish Services Market for Cartridges in Europe, 2019-2030: Distribution by Scale of Operation

14.5.4.5.    Biologics Fill / Finish Services Market for Cartridges in Europe, 2019-2030: Distribution by Type of Biologic

14.5.4.6.    Biologics Fill / Finish Services Market for Cartridges in Europe, 2019-2030: Distribution by Therapeutic Area

14.5.4.7.    Biologics Fill / Finish Services Market for Cartridges in Asia Pacific, 2019-2030: Distribution by Scale of Operation

14.5.4.8.    Biologics Fill / Finish Services Market for Cartridges in Asia Pacific, 2019-2030: Distribution by Type of Biologic

14.5.4.9.    Biologics Fill / Finish Services Market for Cartridges in Asia Pacific, 2019-2030: Distribution by Therapeutic Area

                

14.6.         Biologics Fill / Finish Services Market for Syringes, 2019-2030

14.6.1.      Biologics Fill / Finish Services Market for Syringes, 2019-2030: Distribution by Scale of Operation

14.6.2.      Biologics Fill / Finish Services Market for Syringes, 2019-2030: Distribution by Type of Biologic

14.6.3.      Biologics Fill / Finish Services Market for Syringes, 2019-2030: Distribution by Therapeutic Area

14.6.4.      Biologics Fill / Finish Services Market for Syringes, 2019-2030: Distribution by Geographical Region

14.6.4.1.    Biologics Fill / Finish Services Market for Syringes in North America, 2019-2030: Distribution by Scale of Operation

14.6.4.2.    Biologics Fill / Finish Services Market for Syringes in North America, 2019-2030: Distribution by Type of Biologic

14.6.4.3.    Biologics Fill / Finish Services Market for Syringes in North America, 2019-2030: Distribution by Therapeutic Area

14.6.4.4.    Biologics Fill / Finish Services Market for Syringes in Europe, 2019-2030: Distribution by Scale of Operation

14.6.4.5.    Biologics Fill / Finish Services Market for Syringes in Europe, 2019-2030: Distribution by Type of Biologic

14.6.4.6.    Biologics Fill / Finish Services Market for Syringes in Europe, 2019-2030: Distribution by Therapeutic Area

14.6.4.7.    Biologics Fill / Finish Services Market for Syringes in Asia Pacific, 2019-2030: Distribution by Scale of Operation

14.6.4.8.    Biologics Fill / Finish Services Market for Syringes in Asia Pacific, 2019-2030: Distribution by Type of Biologic

14.6.4.9.    Biologics Fill / Finish Services Market for Syringes in Asia Pacific, 2019-2030: Distribution by Therapeutic Area

 

14.7.         Biologics Fill / Finish Services Market for Vials, 2019-2030

14.7.1.      Biologics Fill / Finish Services Market for Vials, 2019-2030: Distribution by Scale of Operation

14.7.2.      Biologics Fill / Finish Services Market for Vials, 2019-2030: Distribution by Type of Biologic

14.7.3.      Biologics Fill / Finish Services Market for Vials, 2019-2030: Distribution by Therapeutic Area

14.7.4.      Biologics Fill / Finish Services Market for Vials, 2019-2030: Distribution by Geographical Region

14.7.4.1.    Biologics Fill / Finish Services Market for Vials in North America, 2019-2030: Distribution by Scale of Operation

14.7.4.2.    Biologics Fill / Finish Services Market for Vials in North America, 2019-2030: Distribution by Type of Biologic

14.7.4.3.    Biologics Fill / Finish Services Market for Vials in North America, 2019-2030: Distribution by Therapeutic Area

14.7.4.4.    Biologics Fill / Finish Services Market for Vials in Europe, 2019-2030: Distribution by Scale of Operation

14.7.4.5.    Biologics Fill / Finish Services Market for Vials in Europe, 2019-2030: Distribution by Type of Biologic

14.7.4.6.    Biologics Fill / Finish Services Market for Vials in Europe, 2019-2030: Distribution by Therapeutic Area

14.7.4.7.    Biologics Fill / Finish Services Market for Vials in Asia Pacific, 2019-2030: Distribution by Scale of Operation

14.7.4.8.    Biologics Fill / Finish Services Market for Vials in Asia Pacific, 2019-2030: Distribution by Type of Biologic

14.7.4.9.    Biologics Fill / Finish Services Market for Vials in Asia Pacific, 2019-2030: Distribution by Therapeutic Area

 

  1. FUTURE GROWTH OPPORTUNITIES

15.1.         Chapter Overview

15.2.         Growing Biopharmaceutical Pipeline

15.3.         Increase in Outsourcing Fill / Finish Activities

15.4.         Rising Focus on Self-Administration

15.5.         Advances in Aseptic Fill / Finish Technologies

15.6.         Growing Opportunities in the Asia-Pacific Region

 

  1. CASE STUDY: ROBOTIC SYSTEMS IN FILL / FINISH OPERATIONS

16.1.         Chapter Overview

16.2.         Contract Service Providers: List of Fill / Finish Equipment

16.3.         Role of Robotic Systems in  Fill / Finish Operations

16.3.1.      Types of Robots Used in Pharmaceutical Operations

16.3.2.      Key Considerations for Selecting a Robotic System

16.3.3.      Advantages of Robotic Systems

16.3.4.      Disadvantages of Robotic Systems

16.4.         Companies Providing Robots for Use in the Pharmaceutical Industry

16.5.         Concluding Remarks

 

  1. CASE STUDY: READY-TO-USE PACKAGING COMPONENTS IN ASEPTIC FILL / FINISH OPERATIONS

17.1.         Chapter Overview

17.2.         Role of Ready-to-Use Packaging Components in Aseptic Fill / Finish Operations

17.2.1.      Advantages of Ready-to-Use Packaging Components

17.2.2.      Disadvantages of Ready-to-Use Packaging Components

17.3.         Companies Providing Ready-to-Use Packaging Components

17.4.         Concluding Remarks

 

  1. CONCLUDING REMARKS

18.1.         Chapter Overview

18.2.         Key Takeaways

 

  1. INTERVIEW TRANSCRIPTS

19.1          Chapter Overview

19.2          HALIX

19.2.1       Interview Transcript: Jos Vergeest, International Business Developer

19.3          IDT Biologika

19.3.1.      Interview Transcript: Gregor Kawaletz, Chief Commercial Officer

19.4          oncomed manufacturing

19.4.1       Interview Transcript: Ales Sima, Business Development Manager

19.5.         Syngene

19.5.1       Interview Transcript: Purushottam Singnurkar, Research Director and Head of Formulation Development

 

  1. APPENDIX 1: TABULATED DATA

 

  1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com


More than 100 industry players and over 60 non-industry players currently claim to manufacture different types of cell therapies, either for in-house requirements or on contract basis


Submitted 90 day(s) ago by Harry sins

 

Owing to various reasons, the demand for cell therapies is anticipated to increase over the coming years. Therefore, both therapy developers and contract service providers may need to strengthen their capabilities and expand available capacity. In this context, automation is expected to be a key enabler within the cell therapy manufacturing and contract services industry

 

To order this 550+ page report, which features 160+ figures and 250+ tables, please visit this link

 

The USD 11 billion (by 2030) financial opportunity within the cell therapy manufacturing market has been analyzed across the following segments:

  • Type of therapy
  • T-cell therapies (CAR-T therapies, TCR therapies, TIL therapies)
  • Dendritic cell therapies
  • Tumor cell therapies
  • NK cell therapies
  • Stem cell therapies

 

  • Source of cells
  • Autologous
  • Allogeneic

 

  • Scale of operation
  • Clinical
  • Commercial

 

  • Purpose of manufacturing
  • Contract manufacturing
  • In-house manufacturing

 

  • Key geographical regions
  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

 

The Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030 report features the following companies, which we identified to be key players in this domain:

  • BioNTech Innovative Manufacturing Services
  • Cell Therapies
  • Cell and Gene Therapy Catapult
  • Center for Cell and Gene Therapy, Baylor College of Medicine
  • Centre for Cell Manufacturing Ireland, National University of Ireland
  • Clinical Cell and Vaccine Production Facility, University of Pennsylvania
  • Cognate BioServices
  • FUJIFILM
  • Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital
  • Hitachi Chemical
  • KBI Biopharma
  • Laboratory for Cell and Gene Medicine, Stanford University
  • Lonza
  • MaSTherCell
  • MEDINET
  • Molecular and Cellular Therapeutics, University of Minnesota
  • Newcastle Cellular Therapies Facility, Newcastle University
  • Nikon CeLL innovation
  • Rayne Cell Therapy Suite, King’s College London
  • Roslin Cell Therapies
  • Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine
  • Sydney Cell and Gene Therapy
  • WuXi Advanced Therapies

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Market Overview

 

  1. Regulatory Landscape

  2. Roadmaps for Overcoming Existing Challenges

 

  1. Automation Technologies for Cell Therapy Manufacturing

  2. Profiles: Industry Players

  3. Profiles: Non-Industry Players

  4. Role of Non-Profit Organizations

  5. Partnerships

  6. Facility Expansions

  7. Capacity Analysis

 

  1. Demand Analysis

 

  1. Cost Price Analysis

 

  1. Make Versus Buy Decision Making Framework

 

  1. Market Sizing and Opportunity Analysis

 

  1. Key Insights

 

  1. SWOT Analysis

 

  1. Conclusion

 

  1. Survey Analysis

 

  1. Interview Transcripts

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com  

 

 

The cell therapy manufacturing market is projected to grow at an annualized rate of >16.5%, till 2030


Submitted 90 day(s) ago by Harry sins

 

Roots Analysis has done a detailed study on Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030, covering various important aspects of the industry and identifying key future growth opportunities.

 

To order this 550+ page report, which features 160+ figures and 250+ tables, please visit this link

 

Key Market Insights

  • More than 100 industry players and over 60 non-industry players currently claim to manufacture different types of cell therapies, either for in-house requirements or on contract basis
  • The market is fragmented, featuring both established players and new entrants, which claim to operate at various scales and manufacture a diverse range of cell therapies
  • In order to cater to the growing needs of clients / sponsors, companies have established presence across different regions; presently, the US, the UK and China are the key hubs for cell therapy manufacturing
  • In recent years, a significant increase in partnership activity has been observed in this domain; in fact, therapy developers have already inked manufacturing deals with both indigenous and international experts
  • In order to enhance core competencies related to the domain, both drug developers and CMOs are actively investing in expanding their existing infrastructure and capabilities
  • Cell therapy manufacturers are also gradually opting to automate various operations in the supply chain; the primary objective is to achieve favorable bench-to-clinic timelines and cut down on production related losses
  • Currently, the installed global capacity for cell therapy manufacturing is estimated to be spread across 2+ million square feet of dedicated cleanroom area distributed across various scales of operation
  • More than 70,000 patients were estimated to have been enrolled in cell therapy related clinical trials; the demand for cell therapies is anticipated to grow significantly over the next decade
  • Revenues from manufacturing operations of T-cell therapies are anticipated to capture higher market share; the benefit will be realized by both autologous and allogeneic therapies across different regions the world
  • Clinical scale manufacturing operations are likely to drive the future market size, taking into consideration both in-house and contract service requirements

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html

 

Table of Contents

 

  1. PREFACE

1.1.      Scope of the Report

1.2.      Research Methodology

1.3.      Chapter Outlines

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.      Context and Background

3.2.      Introduction to Cell Therapies

3.2.1.    Comparison of Cell Therapies and Other Biotechnology Products

3.2.2.    Classification of Advanced Therapy Medicinal Products (ATMPs)

3.2.3.    Current Market Landscape of ATMPs

 

3.3.      Overview of Cell Therapy Manufacturing

3.4.      Cell Therapy Manufacturing Models

3.4.1.    Centralized Manufacturing

3.4.2.    Decentralized Manufacturing

3.5.      Scalability of Cell Therapy Manufacturing

3.5.1.    Scale-up

3.5.2.    Scale-out

 

3.6.      Types of Cell Therapy Manufacturers

3.7.      Key Manufacturing-related Challenges

3.8.      Factors Influencing Cell Therapy Manufacturing

3.9.      Automating Cell Therapy Manufacturing

3.10.     Cell Therapy Manufacturing Supply Chain

3.11.     Future Perspectives

 

  1. MARKET OVERVIEW

4.1.      Chapter Overview

4.2.      Cell Therapy Manufacturers (Industry Players): Overall Market Landscape

4.2.1.    Analysis by Location of Headquarters

4.2.2.    Analysis by Location of Manufacturing Facility

4.2.3.    Analysis by Type of Cells Manufactured

4.2.4.    Analysis by Source of Cells

4.2.5.    Analysis by Scale of Operation

4.2.6.    Analysis by Type of Cell Culture

4.2.7.    Analysis by Purpose of Production

4.2.8.    Analysis by Manufacturing Capabilities / Services

 

4.3.      Cell Therapy Manufacturers (Non-Industry Players): Overall Market Landscape

4.3.1.    Analysis by Location of Headquarters

4.3.2.    Analysis by Location of Manufacturing Facility

4.3.3.    Analysis by Type of Cells Manufactured

4.3.4.    Analysis by Source of Cells

4.3.5.    Analysis by Scale of Operation

4.3.6.    Analysis by Type of Cell Culture

4.3.7.    Analysis by Purpose of Production

4.3.8.    Analysis by Manufacturing Capabilities / Services

 

4.4.      Cell Therapy Manufacturing: Role of Logistics Service Providers

 

  1. REGULATORY LANDSCAPE

5.1.      Chapter Overview

5.2.      Current Scenario

5.2.1.    Regulatory Guidelines in the US

5.2.2.    Regulatory Guidelines in Europe

5.2.3.    Regulatory Guidelines in Japan

5.2.4.    Conditional Approvals

 

5.3.      Regulatory Accreditations for Cell Therapy Manufacturing

5.3.1.    Facilities Approved by Regulators to Manufacture Cell Therapies

5.4.      Summary of Guidelines for Clinical-Stage Manufacturing of Cell Therapies

5.5.      Existing Challenges to Clinical-Stage Manufacturing

5.5.1.    Variability in Regulatory Guidelines across Different Geographies

5.6.      Conclusion

  1. ROADMAPS FOR OVERCOMING EXISTING CHALLENGES

6.1.      Chapter Overview

6.2.      Roadmap for the US

6.2.1.    Cell Processing

6.2.2.    Cell Preservation, Distribution and Handling

6.2.3.    Process Automation and Data Analytics

6.2.4.    Process Monitoring and Quality Control

6.2.5.    Standardization and Regulatory Support

6.2.6.    Workforce Development

6.2.7.    Supply Chain and Logistics

 

6.3.      Roadmaps for Other Geographies

6.3.1.    Europe

6.3.2.    Asia Pacific

 

  1. AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING

7.1.      Chapter Overview

7.2.      Automation of Cell Therapy Manufacturing Processes

7.2.1.    Closed Systems

7.2.2.    Single-use Systems

7.2.3.    Modular Systems

7.3.      Case Studies

7.3.1.    Roadmap to Developing an Automated Cell Manufacturing / Processing Device

7.3.2.    Automating Cell Therapy Manufacturing

7.4.      GMP-in-a-Box

7.5.      List of Automation Service Providers

7.6.      Comparative Analysis of Manual and Automated Processes

7.7.      Concluding Remarks

 

  1. PROFILES: INDUSTRY PLAYERS

8.1.      Chapter Overview

8.2.      Service Providers in the US

8.2.1     Cognate BioServices

8.2.1.1. Company Overview

8.2.1.2. Service Portfolio

8.2.1.3. Manufacturing Capabilities

8.2.1.4. Partnerships

8.2.1.5. Future Outlook

 

8.2.2.    FUJIFILM Cellular Dynamics

8.2.2.1. Company Overview

8.2.2.2. Service Portfolio

8.2.2.3. Manufacturing Capabilities

8.2.2.4. Partnerships

8.2.2.5. Future Outlook

 

 

8.2.3.    KBI Biopharma

8.2.3.1. Company Overview

8.2.3.2. Service Portfolio

8.2.3.3. Manufacturing Capabilities

8.2.3.4. Partnerships

8.2.3.5. Future Outlook

 

8.2.4.    Hitachi Chemical Advanced Therapeutics Solutions

8.2.4.1. Company Overview

8.2.4.2. Service Portfolio

8.2.4.3. Manufacturing Capabilities

8.2.4.4. Partnerships

8.2.4.5. Future Outlook

 

8.2.5.    Waisman Biomanufacturing

8.2.5.1. Company Overview

8.2.5.2. Service Portfolio

8.2.5.3. Manufacturing Capabilities

8.2.5.4. Partnerships

8.2.5.5. Future Outlook

 

8.3.      Service Providers in Europe

8.3.1.    BioNTech Innovative Manufacturing Services

8.3.1.1. Company Overview

8.3.1.2. Service Portfolio

8.3.1.3. Manufacturing Capabilities

8.3.1.4. Partnerships

8.3.1.5. Future Outlook

 

8.3.2.    Cell and Gene Therapy Catapult

8.3.2.1. Company Overview

8.3.2.2. Service Portfolio

8.3.2.3. Manufacturing Capabilities

8.3.2.4. Partnerships

8.3.2.5. Future Outlook

 

 

8.3.3.    Lonza

8.3.3.1. Company Overview

8.3.3.2. Service Portfolio

8.3.3.3. Manufacturing Capabilities

8.3.3.4. Partnerships

8.3.3.5. Future Outlook

 

8.3.4.    MaSTherCell

8.3.4.1. Company Overview

8.3.4.2. Service Portfolio

8.3.4.3. Manufacturing Capabilities

8.3.4.4. Partnerships

8.3.4.5. Future Outlook

 

8.3.5.    Roslin Cell Therapies

8.3.5.1. Company Overview

8.3.5.2. Service Portfolio

8.3.5.3. Manufacturing Capabilities

8.3.5.4. Partnerships

8.3.5.5. Future Outlook

 

8.4.      Service Providers in Asia Pacific

8.4.1.    Cell Therapies

8.4.1.1. Company Overview

8.4.1.2. Service Portfolio

8.4.1.3. Manufacturing Capabilities

8.4.1.4. Partnerships

8.4.1.5. Future Outlook

 

8.4.2.    Japan Tissue Engineering (J-TEC)

8.4.2.1. Company Overview

8.4.2.2. Service Portfolio

8.4.2.3. Manufacturing Capabilities

8.4.2.4. Partnerships

8.4.2.5. Future Outlook

 

8.4.3.    MEDINET

8.4.3.1. Company Overview

8.4.3.2. Service Portfolio

8.4.3.3. Manufacturing Capabilities

8.4.3.4. Partnerships

8.4.3.5. Future Outlook

 

8.4.4.    Nikon CeLL innovation

8.4.4.1. Company Overview

8.4.4.2. Service Portfolio

8.4.4.3. Manufacturing Capabilities

8.4.4.4. Partnerships

8.4.4.5. Future Outlook

 

8.4.5.    WuXi Advanced Therapies

8.4.5.1. Company Overview

8.4.5.2. Service Portfolio

8.4.5.3. Manufacturing Capabilities

8.4.5.4. Partnerships

8.4.5.5. Future Outlook

 

  1. PROFILES: NON-INDUSTRY PLAYERS

9.1.      Chapter Overview

9.2.      Center for Cell and Gene Therapy, Baylor College of Medicine

9.2.1.    Overview

9.2.2.    Operating Segments

9.2.3.    Service Portfolio

9.2.4.    Manufacturing Facilities and Capabilities

 

9.3.      Centre for Cell Manufacturing Ireland, National University of Ireland

9.3.1.    Overview

9.3.2.    Service Portfolio

9.3.3.    Manufacturing Facilities and Capabilities

 

9.4.      Clinical Cell and Vaccine Production Facility, University of Pennsylvania

9.4.1.    Overview

9.4.2.    Service Portfolio

9.4.3.    Manufacturing Facilities and Capabilities

 

9.5.      Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital

9.5.1.    Overview

9.5.2.    Service Portfolio

9.5.3.    Manufacturing Facilities and Capabilities

 

9.6.      Laboratory for Cell and Gene Medicine, Stanford University

9.6.1.    Overview

9.6.2.    Service Portfolio

9.6.3.    Manufacturing Facilities and Capabilities

 

9.7.      Molecular and Cellular Therapeutics, University of Minnesota

9.7.1.    Overview

9.7.2.    Service Portfolio

9.7.3.    Manufacturing Facilities and Capabilities

 

9.8.      Newcastle Cellular Therapies Facility, Newcastle University

9.8.1.    Overview

9.8.2.    Service Portfolio

9.8.3.    Manufacturing Facilities and Capabilities

 

9.9.      Rayne Cell Therapy Suite, King’s College London

9.9.1.    Overview

9.9.2.    Manufacturing Facilities and Capabilities

 

9.10.     Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine

9.10.1.  Overview

9.10.2.  Manufacturing Facilities and Capabilities

 

9.11.     Sydney Cell and Gene Therapy

9.11.1.  Overview

9.11.2.  Manufacturing Facilities and Capabilities

 

  1. ROLE OF NON-PROFIT ORGANIZATIONS

10.1.     Chapter Overview

10.2.     Cell Therapy Manufacturing Service Providers: Non-Profit Organizations

10.2.1.  CellCAN

10.2.2.  Cell Therapy Manufacturing Cooperative Research Center (CTM CRC)

10.2.3.  National Cell Manufacturing Consortium (NCMC)

10.2.4.  California Institute of Regenerative Medicine (CIRM)

10.3.     Cell Therapy Manufacturing: Affiliated International Societies

 

  1. PARTNERSHIPS

11.1.     Chapter Overview

11.2.     Partnership Models

 

11.3.     Cell Therapy Manufacturing: List of Partnerships

11.3.1.  Analysis by Year of Partnership

11.3.2.  Analysis by Type of Partnership Model

11.3.3.  Analysis by Year and Type of Partnership Model

 

11.4.     Analysis by Type of Cells

11.5.     Analysis by Scale of Operation

11.6.     Geographical Analysis

11.6.1.  Continent-wise Distribution

11.6.2.  Country-wise Distribution

11.7.     Most Active Players: Analysis by Number of Partnerships

 

11.8.     Cell Therapy Manufacturing: List of Acquisitions

11.8.1.  Analysis by Year and Type of Cells

11.8.2.  Geographical Analysis

11.8.3.  Ownership Change Matrix

 

  1. FACILITY EXPANSIONS

12.1.     Chapter Overview

12.2.     Cell Therapy Manufacturing: List of Expansions

12.2.1.  Cumulative Year-wise Distribution

12.2.2.  Analysis by Type of Cells

12.2.3.  Analysis by Scale of Operation

12.2.3.  Analysis by Purpose of Expansion 

12.2.4.  Analysis by Location of Manufacturing Facility

12.2.5.  Analysis by Region and Purpose of Expansion

 

  1. CAPACITY ANALYSIS

13.1.     Chapter Overview

13.2.     Key Assumptions and Methodology (Industry Players)

13.2.1   Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)

13.2.1.1. Analysis by Size of Manufacturer

13.2.1.2. Analysis by Scale of Operation

13.2.1.3. Analysis by Location of Manufacturing Facility

13.2.2.  Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)

13.2.2.1. Analysis by Size of Manufacturer

13.2.2.2. Analysis by Scale of Operation

13.2.2.3. Analysis by Location of Manufacturing Facility

 

13.3.     Key Assumptions and Methodology (Non-Industry Players)

13.3.1.  Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)

13.3.1.1. Analysis by Scale of Operation

13.3.1.2. Analysis by Location of Manufacturing Facility

 

13.3.2.  Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)

13.3.2.1. Analysis by Scale of Operation

13.3.2.2. Analysis by Location of Manufacturing Facility

13.4      Concluding Remarks

 

  1. DEMAND ANALYSIS

14.1      Chapter Overview

14.2      Key Assumptions and Methodology

14.3      Cell Therapy Manufacturing: Overall Annual Demand

14.3.1.  Analysis by Type of Cells

14.3.2.  Analysis by Scale of Operations

14.3.3.  Analysis by Geography

 

  1. COST PRICE ANALYSIS

15.1.     Chapter Overview

15.2.     Factors Contributing to the High Price of Cell Therapies

15.3.     Pricing Models for Cell Therapies

15.3.1.  Based on Associated Costs for T-cell Therapies

15.3.2.  Based on Associated Costs for Stem Cell Therapies

15.3.3.  Based on Availability of Competing Products

15.3.4.  Based on Target Patient Segment

15.3.5.  Based on Opinions of Industry Experts

15.4.     Cell Therapy Cost Optimization

15.4.1.  Role of Cost of Goods Sold

15.4.2.  Role of Automation

15.4.3.  Role of Cell Therapy Contract Manufacturing Organizations

15.5.     Reimbursement-related Considerations for Cell Therapies

15.5.1.  Case Study: The National Institute for Health and Care Excellence’s (NICE) Appraisal of CAR-T Therapies

 

  1. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

16.1.     Chapter Overview

16.2.     Make versus Buy Decision Making: Analytical Output

 

  1. MARKET SIZING AND OPPORTUNITY ANALYSIS

17.1.     Chapter Overview

17.2.     Scope of the Forecast

17.3.     Forecast Methodology

17.4.     Input Tables and Key Assumptions

17.5.     Overall Cell Therapy Manufacturing Market, 2019-2030

17.5.1.  Cell Therapy Manufacturing Market, 2019-2030: Distribution by Type of Cell Therapy

17.5.2.  Cell Therapy Manufacturing Market, 2019-2030: Distribution by Source of Cells

17.5.3.  Cell Therapy Manufacturing Market, 2019-2030: Distribution by Scale of Operation

17.5.4.  Cell Therapy Manufacturing Market, 2019-2030: Distribution by Purpose of

            Production     

17.5.5.  Cell Therapy Manufacturing Market, 2019-2030: Geographical Distribution

 

17.6.     Market Opportunity in Commercial Scale Manufacturing of Cell-based Therapies

17.6.1.  Overall Commercial Scale Manufacturing Market for T-cell Therapies, 2019-2030

17.6.1.1. Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy, and TIL Therapy)

17.6.1.2. Distribution by Source of Cells

17.6.1.3. Geographical Distribution

 

17.6.2.  Overall Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2019-2030

17.6.2.1. Distribution by Type of Therapy (Dendritic Cell Therapy, and Tumor Cell Therapy)

17.6.2.2. Distribution by Source of Cells

17.6.2.3. Geographical Distribution

 

17.6.3.  Overall Commercial Scale Manufacturing Market for NK Cell Therapies, 2019-2030

17.6.3.1. Distribution by Source of Cells

17.6.3.2. Geographical Distribution

 

 

17.6.4.  Overall Commercial Scale Manufacturing Market for Stem Cell Therapies, 2019-2030

17.6.4.1. Distribution by Source of Cells

17.6.4.2. Geographical Distribution

17.7.     Market Opportunity in Clinical Scale Manufacturing of Cell-based Therapies

17.7.1.  Overall Clinical Scale Manufacturing Market for T-cell Therapies, 2019-2030

17.7.1.1. Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy and TIL Therapy)

17.7.1.2. Distribution by Source of Cells

17.7.1.3. Geographical Distribution

 

17.7.2.  Overall Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2019-2030

17.7.2.1. Distribution by Type of Therapy (Dendritic Cell Therapy, Tumor Cell Therapy)

17.7.2.2. Distribution by Source of Cells

17.7.2.3. Geographical Distribution

 

17.7.3.  Overall Clinical Scale Manufacturing Market for NK Cell Therapies, 2019-2030

17.7.3.1. Distribution by Source of Cells

17.7.3.2. Geographical Distribution

 

17.7.4.  Overall Clinical Scale Manufacturing Market for Stem Cell Therapies, 2019-2030

17.7.4.1. Distribution by Source of Cells

17.7.4.2. Geographical Distribution

 

  1. KEY INSIGHTS

18.1.     Chapter Overview

18.2.     Cell Therapy Manufacturers: Grid Analysis

18.3.     Cell Therapy Manufacturers: Logo Landscape by Type of Cell Therapy

18.3.1.  Logo Landscape: Immune Cell Manufacturers

18.3.2.  Logo Landscape: Stem Cell Manufacturers

18.4.     Cell Therapy Manufacturers: World Map Representation of Location of Manufacturing Facility

18.4.1.  Industry Players

18.4.2.  Non-Industry Players

 

  1. SWOT ANALYSIS

19.1.     Chapter Overview

19.2.     Strengths

19.3.     Weaknesses

19.4.     Opportunities

19.5.     Threats

19.6.     Comparison of SWOT Factors

19.6.1.  Concluding Remarks

 

  1. CONCLUSION

20.1.     Chapter Overview

20.2.     Key Takeaways

 

  1. SURVEY ANALYSIS

21.1.     Chapter Overview

21.2.     Seniority Level of Respondents

21.3.     Type of Cell Therapy

21.4.     Scale of Operation

21.5.     Source of Cells

21.6.     Type of Cell Culture System

22.7.     Availability of Fill / Finish Services

 

 

  1. INTERVIEW TRANSCRIPTS

22.1.     Chapter Overview

22.2.     Lion TCR

22.2.1.  Company Overview

22.2.2.  Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer

 

22.3.     Cell Therapies

22.3.1.  Company Overview

22.3.2.  Interview Transcript: Tim Oldham, Chief Executive Officer 

 

22.4.     CiMaas

22.4.1.  Company Overview

22.4.2.  Interview Transcript: Gerard MJ Bos, Chief Executive Officer

 

22.5.     Gracell Biotechnologies

22.5.1.  Company Overview

22.5.2.  Interview Transcript:  Wei (William) Cao, Chief Executive Officer

 

22.6.     Glycostem Therapeutics

22.6.1.  Company Overview

22.6.2.  Interview Transcript: Troels Jordansen, Chief Executive Officer

 

22.7.     Kadimastem

22.7.1.  Company Overview

22.7.2.  Interview Transcript: Arik Hasson, Executive VP Research and Development

 

22.8.     Bio Elpida

22.8.1.  Company Overview

22.8.2.  Interview Transcript: Gilles Devillers, General Manager

 

22.9.     Center for Commercialization of Cancer Immunotherapy / C3i

22.9.1.  Company Overview

22.9.2.  Interview Transcript: Arnaud Deladeriere, Manager, Business Development & Operations-cGMP Manufacturing Unit

 

22.10.   Waisman Biomanufacturing

22.10.1. Company Overview

22.10.2. Interview Transcript: Brian Dattilo, Manager of Business Development

 

22.11.   RoslinCT

22.11.1. Company Overview

22.11.2. Interview Transcript: Fiona Bellot, Business Development Manager

 

22.12.   Yposkesi

22.12.1. Company Overview

22.12.2. Interview Transcript: Mathilde Girard, Leader, Cell Therapy Innovation and Development

 

22.13.   University of Minnesota

22.13.1. Organization Overview

22.13.2. Interview Transcript: David Mckenna, Professor and American Red in Transfusion Medicine

 

  1. APPENDIX 1: TABULATED DATA

 

  1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

The “Encapsulated Cell Therapies and Encapsulation Technologies Market” report features an extensive study of the current market landscape and future potential, offering an informed opinion on the likely adoption of these therapies / technologies over the


Submitted 91 day(s) ago by Harry sins

 

To order this 500+ page report, please visit this link

 

Key Inclusions

  • A detailed assessment of the current market landscape of encapsulated cell therapies and affiliated technologies, highlighting various target disease indications, phase of development, encapsulation method, type of cells / API, and route of administration, along with information on various stakeholder companies that are developing novel encapsulation methods / techniques for use in storage and transportation of cells, as well as other applications.
  • Comprehensive profiles of industry players that are currently engaged in the preclinical / clinical development of their proprietary encapsulated cell therapies, featuring an overview of the company, its financial information (if available), and a detailed description of its product(s), highlighting mechanism of action, current development status, and key preclinical / clinical trial results. Each profile also includes a list of recent developments, highlighting the key milestones achieved, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the in the foreseen future.
  • An in-depth analysis of the patents that have been published related to cell encapsulation technologies, since 2013. The analysis also highlights the key trends associated with these patents, across patent type, regional applicability, CPC classification, emerging focus areas, leading industry players (in terms of number of patents filed / granted), and current intellectual property-related benchmarks and valuation.
  • A comprehensive clinical trial analysis of completed, ongoing and planned studies of various encapsulated cell therapies. The analysis highlights the key trends associated with these clinical studies across various parameters, such as trial start year, trial status, phase of development, leading industry and non-industry players (in terms of number of trials conducted), study design, target therapeutic area, key indications, study focus, clinical endpoints, and enrolled patient population and regional distribution of trials.
  • An analysis of the partnerships that have been established in the domain in the period 2013-2018, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, manufacturing agreements, clinical trial agreements, process development agreements, and other relevant deals.
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies that are focused in this area.
  • A detailed study on the various grants that have been awarded to research institutes in this field.
  • An analysis highlighting potential strategic partners (for instance, manufacturers) for encapsulated therapy developers based on multiple parameters, such as therapeutic focus overlap, cell type overlap, research programs, existing collaborations, and developer strength.

 

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

  • Type of licensing deal payment
  • Upfront payment
  • Milestone payment

 

  • Therapeutic area
  • Metabolic disorder
  • Neurological disorder
  • Ophthalmic disorder
  • Oncological disorder

 

  • Target disease indication
  • Ataxia telangiectasia
  • Breast cancer
  • Diabetes
  • Glaucoma
  • Head and neck cancer
  • Macular telangectasia
  • Pancreatic cancer
  • Parkinson's disease
  • Retinitis pigmentosa

 

  • Type of encapsulation material used
  • Alginate-based microcapsule
  • Cellulose hydrogel
  • Medical-grade plastic
  • Red blood cell

 

  • Key geographical region
  • North America
  • Europe
  • Asia-Pacific and rest of the world

 

To request sample pages, please visit this link

 

Key Questions Answered

  • What are the prevalent R&D trends related to cell encapsulation technologies?
  • Which clinical conditions can be treated using encapsulated cell therapy products?
  • What are the key challenges faced by stakeholders engaged in this domain?
  • What are the key technology platforms that leverage the concept of cell encapsulation?
  • Who are the leading industry and non-industry players in this market?
  • What are the key geographies where research on encapsulated cell therapies is being conducted?
  • Who are the key investors in this domain?
  • Who are the key thought leaders with expertise in cell encapsulation technologies?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • Who are the potential strategic partners (for instance, manufacturers) for encapsulated therapy developers?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the factors that are likely to influence the evolution of this upcoming market?

 

You may also be interested in the following titles:

  1. Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous Delivery Devices
  2. Endocannabinoid System Targeted Therapeutics Market, 2020-2030
  3. Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030

 

Contact:

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com

 

More than 45 encapsulated cell therapies and encapsulation technologies are being evaluated across different phases of development by stakeholders across the globe, claims Roots Analysis


Submitted 91 day(s) ago by Harry sins

 

Extensive research on cell encapsulation strategies has enabled the development of a variety of technologies capable of immobilizing / enclosing therapeutic entities within biocompatible matrices / carriers. Such products offer a myriad of advantages, and have demonstrated the capability to address existing challenges related to cell therapies and certain other types of interventions as well.

 

To order this 500+ page report, which features 170+ figures and 395+ tables, please visit this link

 

The USD 3.7 billion (by 2030) financial opportunity within the encapsulated cell therapies and encapsulation technologies market has been analyzed across the following segments:

  • Type of licensing deal payment
  • Upfront payment
  • Milestone payment

 

  • Therapeutic area
  • Metabolic disorder
  • Neurological disorder
  • Ophthalmic disorder
  • Oncological disorder

 

  • Target disease indication
  • Ataxia telangiectasia
  • Breast cancer
  • Diabetes
  • Glaucoma
  • Head and neck cancer
  • Macular telangectasia
  • Pancreatic cancer
  • Parkinson's disease
  • Retinitis pigmentosa

 

  • Type of encapsulation material used
  • Alginate-based microcapsule
  • Cellulose hydrogel
  • Medical-grade plastic
  • Red blood cell

 

  • Key geographical region
  • North America
  • Europe
  • Asia-Pacific and rest of the world

 

The Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030 report features the following companies, which we identified to be key players in this domain: 

  • ALTuCELL
  • Azellon Cell Therapeutics
  • Beta-Cell
  • Betalin Therapeutics
  • CellProtect Biotechnology
  • Diatranz Otsuka
  • Encellin
  • EryDel
  • Gloriana Therapeutics
  • Living Cell Technologies
  • MaxiVAX
  • Neurotech Pharmaceuticals
  • PharmaCyte Biotech
  • Semma Therapeutics
  • Sernova

 

Table of Contents

 

  1. Preface

  2. Executive Summary

 

  1. Introduction

 

  1. Current Market Landscape

 

  1. Encapsulated Cell Therapies and Encapsulation Technologies for Metabolic Disorders: Company Profiles

 

  1. Encapsulated Cell Therapies and Encapsulation Technologies for Non-Metabolic Disorders: Company Profiles

 

  1. Patent Analysis

 

  1. Clinical Trial Analysis

 

  1. Recent Partnerships

 

  1. Funding and Investment Analysis

 

  1. Grant Analysis

 

  1. Potential Strategic Partners

 

  1. Market Forecast

 

  1. Conclusion

 

  1. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://rootsanalysis.com/reports/view_document/cell-encapsulation-focus-on-therapeutics-and-technologies-2019-2030/249.html

 

Contact:

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com

 

 

Given the increasing number of licensing deals and the expected approval of multiple mid-late stage candidates, the encapsulated cell therapies and encapsulation technologies market is anticipated to evolve at a rapid pace over the next decade, predicts R


Submitted 91 day(s) ago by Harry sins

 

 

Roots Analysis has done a detailed study on Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 500+ page report, which features 170+ figures and 395+ tables, please visit this link

 

Key Market Insights

  • Presently, over 45 encapsulated cell therapies and encapsulation technologies are being evaluated across different phases of development by stakeholders across the world
  • Ongoing therapy development programs are evaluating different types of cells, encapsulated in a wide range of biocompatible materials, aiming to offer viable and effective treatment options for various diseases
  • In fact, majority of the product candidates are being developed for the treatment of metabolic disorders, primarily diabetes; big pharma are driving a significant proportion of research and development activity
  • Clinical research in this field is growing at a fast pace; encapsulated therapy products are evaluating a number of pre-marketing end points to validate safety / efficacy
  • Over the years, more than 3,000 patents have been granted / filed related to cell encapsulation technologies, demonstrating the heightened pace of research in this domain
  • Foreseeing a lucrative future, several private and public investors have made capital investments worth approximately USD 1 billion, across over 100 funding instances, since 2013
  • Growth in partnership activity reflects the rising interest of stakeholders in this domain; over 70% of deals have been inked related to therapies for metabolic disorders, involving both international and indigenous parties
  • An evaluation of more than 300+ stakeholders engaged in cell therapies domain reveals the presence of several likely strategic partners spread across different geographical regions
  • The short term opportunity in this market is likely to be driven by licensing activity and will depend on the untapped potential of novel cell encapsulation technologies in different application areas
  • As multiple mid-late stage encapsulated cell therapies get commercialized in near future across different regions, the long term opportunity is likely to be distributed across diverse indications and encapsulation materials
  • The enormous potential of encapsulated cell-based therapies / devices in the treatment of chronic disorders has captured the interest of several stakeholders in the industry

 

For more information, please visit https://rootsanalysis.com/reports/view_document/cell-encapsulation-focus-on-therapeutics-and-technologies-2019-2030/249.html

 

Table of Contents

 

  1. PREFACE

1.1.                  Scope of the Report

1.2.                  Research Methodology

1.3.                  Chapter Outlines


  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.                  Context and Background

3.2.                  An Overview of Cell Therapies

3.2.1.                Cell Therapy Manufacturing

3.2.2.                Supply Chain

3.2.3.                Key Challenges

 

3.3.                  An Introduction to Cell Encapsulation

3.3.1.                Historical Overview

3.3.2.                Cell Encapsulation Approaches

3.3.3.                Encapsulation Materials

3.3.4.                Advantages and Challenges

 

3.4.                  Potential Applications of Cell Encapsulation

3.4.1.                Targeted Drug / Therapy Delivery

3.4.2.                Immunoprotection

3.4.3.                Storage and Transportation

 

3.5.                  Key Growth Drivers and Road-blocks

 

  1. CURRENT MARKET LANDSCAPE

4.1.                  Chapter Overview

4.2.                  Encapsulated Cell Therapies and Encapsulation Technologies: Developer Landscape

4.2.1.                Distribution by Year of Establishment

4.2.2.                Distribution by Geographical Location

4.2.3.                Distribution by Size of Developers

4.2.4.                Distribution by Type of Offering

 

4.3.                  Encapsulated Cell Therapies and Encapsulation Technologies: Development Pipeline

4.3.1.                Distribution by Target Therapeutic Area

4.3.2.                Distribution by Phase of Development

4.3.3.                Distribution by Type of Cells and Other Encapsulated Components

4.3.4.                Distribution by Type of Encapsulation Material Used

4.3.5.                Distribution by Route of Administration

4.3.6.                Distribution by Application Areas

 

4.4.                  Encapsulated Cell Therapies and Encapsulation Technologies: Initiatives of Big Pharmaceutical Players

 

  1. ENCAPSULATED CELL THERAPIES AND ENCAPSULATION TECHNOLOGIES FOR METABOLIC DISORDERS: COMPANY PROFILES

5.1.                  Chapter Overview

5.2.                  Developers with Clinical Candidates

5.2.1.               Beta-O2 Technologies

5.2.1.1.            Company Overview

5.2.1.2.            Financial Information

5.2.1.3.            Product Description: ꞵAir Bio-artificial Pancreas

5.2.1.4.            Recent Developments and Future Outlook

 

5.2.2.               Diatranz Otsuka

5.2.2.1.            Company Overview

5.2.2.2.            Financial Information

5.2.2.3.            Product Description: DIABECELL®

5.2.2.4.            Recent Developments and Future Outlook

 

5.2.3.               Sernova

5.2.3.1.            Company Overview

5.2.3.2.            Financial Information

5.2.3.3.            Product Description: Cell Pouch System™

5.2.3.4.            Recent Developments and Future Outlook

 

5.2.4.               ViaCyte

5.2.4.1.            Company Overview

5.2.4.2.            Financial Information

5.2.4.3.            Product Description: PEC-Direct™ and PEC-Encap™

5.2.4.4.            Recent Developments and Future Outlook

 

5.3.                  Developers with Preclinical Candidates

5.3.1.               ALTuCELL

5.3.2.               Beta-Cell

5.3.3.               Betalin Therapeutics

5.3.4.               CellProtect Biotechnology

5.3.5.               Defymed

5.3.6.               Encellin

5.3.7.               Kadimastem

5.3.8.               PharmaCyte Biotech

5.3.9.               Semma Therapeutics

5.3.10.             Sigilon Therapeutics

5.3.11.             Seraxis

5.3.12.             SymbioCellTech

 

  1. ENCAPSULATED CELL THERAPIES AND ENCAPSULATION TECHNOLOGIES FOR NON-METABOLIC DISORDERS: COMPANY PROFILES

6.1.                  Chapter Overview

6.2.                  Developers with Clinical Candidates

6.2.1.               Azellon Cell Therapeutics

6.2.1.1.            Company Overview

6.2.1.2.            Financial Information

6.2.1.3.            Product Description: Cell Bandage

6.2.1.4.            Recent Developments and Future Outlook

 

6.2.2.               EryDel

6.2.2.1.            Company Overview

6.2.2.2.            Financial Information

6.2.2.3.            Product Description: EryDex System

6.2.2.4.            Recent Developments and Future Outlook

 

6.2.3.               Erytech Pharma

6.2.3.1.            Company Overview

6.2.3.2.            Financial Information

6.2.3.3.            Product Description: GRASPA®

6.2.3.4.            Recent Developments and Future Outloo

 

6.2.4.               Gloriana Therapeutics

6.2.4.1.            Company Overview

6.2.4.2.            Financial Information

6.2.4.3.            Product Description: EC-NGF

6.2.4.4.            Recent Developments and Future Outlook

 

6.2.5.               Living Cell Technologies

6.2.5.1.            Company Overview

6.2.5.2.            Financial Information

6.2.5.3.            Product Description: NTCELL®

6.2.5.4.            Recent Developments and Future Outlook

 

6.2.6.               MaxiVAX

6.2.6.1.            Company Overview

6.2.6.2.            Financial Information

6.2.6.3.            Product Description: MVX-ONCO-1

6.2.6.4.            Recent Developments and Future Outlook

 

6.2.7.               Neurotech Pharmaceuticals

6.2.7.1.            Company Overview

6.2.7.2.            Financial Information

6.2.7.3.            Product Description: NT-501

6.2.7.4.            Recent Developments and Future Outlook

 

6.2.8.               PharmaCyte Biotech

6.2.8.1.            Company Overview

6.2.8.2.            Financial Information

6.2.8.3.            Product Description: Cell-in-a-Box®

6.2.8.4.            Recent Developments and Future Outlook

 

6.3.                  Developers with Preclinical Candidates

6.3.1.               Beta-O2 Technologies

6.3.2.               Sernova

6.3.3.               Sigilon Therapeutics

 

  1. PATENT ANALYSIS

7.1.                  Chapter Overview

7.2.                  Scope and Methodology

7.3.                  Encapsulated Cell Therapies and Encapsulation Technologies: Patent Analysis

7.3.1.               Analysis by Publication Year

7.3.2.               Analysis by Geographical Location

7.3.3.               Analysis by CPC Classifications

7.3.4.               Emerging Focus Areas

7.3.5.               Leading Players: Analysis by Number of Patents

 

7.4.                  Encapsulated Cell Therapies and Encapsulation Technologies: Patent Benchmarking Analysis (Industry Players)

7.4.1.               Analysis by Patent Characteristics

7.4.2.               Analysis by Geographical Locatio

 

7.5.                  Encapsulated Cell Therapies and Encapsulation Technologies: Patent Valuation Analysis

7.6.                  Leading Patents: Analysis by Number of Citations

 

  1. CLINICAL TRIAL ANALYSIS

8.1.                  Chapter Overview

8.2.                  Scope and Methodology

8.3.                  Encapsulated Cell Therapies and Encapsulation Technologies: List of Clinical Trials

8.3.1.               Analysis by Trial Registration Year

8.3.2.               Geographical Analysis by Number of Clinical Trials

8.3.3.               Geographical Analysis by Enrolled Patient Population

8.3.4.               Analysis by Phase of Development

8.3.5.               Analysis by Study Design

8.3.6.               Analysis by Type of Sponsor / Collaborator

8.3.7.               Most Active Players: Analysis by Number of Registered Trials

8.3.8.               Analysis by Trial Focus

8.3.9.               Analysis by Therapeutic Area

8.3.10.             Analysis by Clinical Endpoints

 

  1. RECENT PARTNERSHIPS

9.1.                  Chapter Overview

9.2.                  Partnership Models

9.3.                  Encapsulated Cell Therapies and Encapsulation Technologies: Recent Collaborations and Partnerships

9.3.1.               Analysis by Year of Partnership

9.3.2.               Analysis by Type of Partnership

9.3.3.               Analysis by Therapeutic Area

9.3.4.               Analysis by Type of Cells and Other Encapsulated Components

9.3.5.               Most Active Players: Analysis by Number of Partnerships

 

9.3.6.               Analysis by Regions

9.3.6.1.            Most Active Players

9.3.6.2.            Intercontinental and Intracontinental Agreements

 

  1. FUNDING AND INVESTMENT ANALYSIS

10.1.                Chapter Overview

10.2.                Types of Funding

10.3.                Encapsulated Cell Therapies and Encapsulation Technologies: Recent Funding Instances

10.3.1.             Analysis by Number of Funding Instances

10.3.2.             Analysis by Amount Invested

10.3.3.             Analysis by Type of Funding

10.3.4.             Analysis by Number of Funding Instances and Amount Invested across Different Indications

10.3.5.             Analysis by Amount Invested across Different Type of Cells and Other Encapsulated Components

10.3.6.             Most Active Players: Analysis by Amount Invested

10.3.7.             Most Active Investors: Analysis by Number of Instances

10.3.8.             Geographical Analysis of Amount Invested

10.4.                Concluding Remarks

 

  1. GRANT ANALYSIS

11.1.                Chapter Overview

11.2.                Scope and Methodology

11.3.                Encapsulated Cell Therapies and Encapsulation Technologies: List of Academic Grants

11.3.1.             Analysis by Project Start Year

11.3.2.             Analysis by Focus Area

11.3.3.             Analysis by Support Period

11.3.4.             Analysis by Type of Grant

11.3.5.             Analysis by Amount Awarded

11.3.6.             Analysis by Study Section

11.3.7.             Analysis by Therapeutic Area

11.3.8.             Analysis by Type of Cells and Other Encapsulated Components

11.3.9.             Analysis by Type of Encapsulation Material

11.3.10.            Leading Funding Institutes: Analysis by Number of Grants

11.3.11.            Leading Recipient Organizations: Analysis by Number of Grants

 

  1. POTENTIAL STRATEGIC PARTNERS

12.1.                Chapter Overview

12.2.                Scope and Methodology

 

12.3.                Potential Strategic Partners for Cell Therapy Development

12.3.1.             Opportunities in North America

12.3.1.1.           Most Likely Partners for Cell Therapy Development

12.3.1.2.           Likely Partners for Cell Therapy Development

12.3.1.3.           Less Likely Partners for Cell Therapy Development

 

12.3.2.             Opportunities in Europe

12.3.2.1.           Most Likely Partners for Cell Therapy Development

12.3.2.2.           Likely Partners for Cell Therapy Development

12.3.2.3.           Less Likely Partners for Cell Therapy Development

 

12.3.3.             Opportunities in Asia-Pacific and Rest of the World

12.3.3.1.           Most Likely Partners for Cell Therapy Development

12.3.3.2.           Likely Partners for Cell Therapy Development

12.3.3.3.           Less Likely Partners for Cell Therapy Development

 

12.4.                Potential Strategic Partners for Cell Therapy Manufacturing

12.4.1.             Opportunities in North America

12.4.1.1.           Most Likely Partners for Cell Therapy Manufacturing

12.4.1.2.           Likely Partners for Cell Therapy Manufacturing

12.4.1.3.           Less Likely Partners for Cell Therapy Manufacturing

 

12.4.2.             Opportunities in Europe

12.4.2.1.           Most Likely Partners for Cell Therapy Manufacturing

12.4.2.2.           Likely Partners for Cell Therapy Manufacturing

12.4.2.3.           Less Likely Partners for Cell Therapy Manufacturing

 

12.4.3.             Opportunities in Asia-Pacific and Rest of the World

12.4.3.1.           Most Likely Partners for Cell Therapy Manufacturing

12.4.3.2.           Likely Partners for Cell Therapy Manufacturing

12.4.3.3.           Less Likely Partners for Cell Therapy Manufacturing

 

  1. MARKET FORECAST

13.1.                Chapter Overview

13.2.                Forecast Methodology and Key Assumptions

13.3.                Overall Cell Encapsulation Technologies Market, 2019-2030

13.3.1.              Cell Encapsulation Technologies Market by Upfront Payments, 2019-2030

13.3.2.              Cell Encapsulation Technologies Market by Milestone Payments, 2019-2030

 

13.4.                Overall Encapsulated Cell Therapies Market, till 2030

13.4.1.             Encapsulated Cell Therapies Market: Distribution by Therapeutic Area

13.4.1.1.           Encapsulated Cell Therapies Market for Eye Disorders, till 2030

13.4.1.2.           Encapsulated Cell Therapies Market for Metabolic Disorders, till 2030

13.4.1.3.           Encapsulated Cell Therapies Market for Neurological Disorders, till 2030

13.4.1.4.           Encapsulated Cell Therapies Market for Oncological Disorders, till 2030

 

13.4.2.             Encapsulated Cell Therapies Market: Distribution by Type of Encapsulation Material Used

13.4.2.1.           Encapsulated Cell Therapies Market for Alginate-based Microcapsules, till 2030

13.4.2.2.           Encapsulated Cell Therapies Market for Cellulose Hydrogels, till 2030

13.4.2.3.           Encapsulated Cell Therapies Market for Medical-grade Plastics, till 2030

13.4.2.4.           Encapsulated Cell Therapies Market for Red Blood Cells, till 2030

 

13.4.3.             Encapsulated Cell Therapies Market: Distribution by Geography

13.4.3.1.           Encapsulated Cell Therapies Market in North America, till 2030

13.4.3.2.           Encapsulated Cell Therapies Market in Europe, till 2030

13.4.3.3.           Encapsulated Cell Therapies Market in Asia-Pacific, till 2030

 

13.5.                Encapsulated Cell Therapies for Eye Disorders: Distribution by Indication

13.5.1.             Encapsulated Cell Therapies Market for Eye Disorders: Macular Telangectasia, till 2030

13.5.1.1.           NT-501 (Neurotech Pharmaceuticals)

13.5.1.1.1.        Target Patient Population

13.5.1.1.2.        Sales Forecast

13.5.1.1.3.        Geographical Distribution of Projected Opportunity

13.5.1.1.3.1.     Projected Opportunity in the US

13.5.1.1.3.2.     Projected Opportunity in EU5

13.5.1.1.3.3.     Projected Opportunity in Rest of Europe

13.5.1.1.3.4.     Projected Opportunity in Australia

 

13.5.2.              Encapsulated Cell Therapies Market for Eye Disorders: Glaucoma, till 2030

13.5.2.1.           NT-501 (Neurotech Pharmaceuticals)

13.5.2.1.1.        Target Patient Population

13.5.2.1.2.        Sales Forecast

13.5.2.1.3.        Geographical Distribution of Projected Opportunity

13.5.2.1.3.1.     Projected Opportunity in the US

13.5.2.1.3.2.     Projected Opportunity in EU5

13.5.2.1.3.3.     Projected Opportunity in Rest of Europe

13.5.2.1.3.4.     Projected Opportunity in Australia

 

13.5.3.              Encapsulated Cell Therapies Market for Eye Disorders: Retinitis Pigmentosa, till 2030

13.5.3.1.           NT-501 (Neurotech Pharmaceuticals)

13.5.3.1.1.        Target Patient Population

13.5.3.1.2.        Sales Forecast

13.5.3.1.3.        Geographical Distribution of Projected Opportunity

13.5.3.1.3.1.     Projected Opportunity in the US

13.5.3.1.3.2.     Projected Opportunity in EU5

13.5.3.1.3.3.     Projected Opportunity in Rest of Europe

13.5.3.1.3.4.     Projected Opportunity in Australia

 

13.6.                 Encapsulated Cell Therapies for Metabolic Disorders: Distribution by Indication

13.6.1.              Encapsulated Cell Therapies Market for Metabolic Disorders: Type 1 Diabetes, till 2030

13.6.1.1.           DIABECELL® (Diatranz Otsuka)

13.6.1.1.1.        Target Patient Population

13.6.1.1.2.        Sales Forecast

13.6.1.1.3.        Geographical Distribution of Projected Opportunity

13.6.1.1.3.1.     Projected Opportunity in the US

13.6.1.1.3.2.     Projected Opportunity in Japan

13.6.1.1.3.3.     Projected Opportunity in EU5

13.6.1.1.3.4.     Projected Opportunity in Rest of Europe

13.6.1.1.3.5.     Projected Opportunity in Australia

13.6.1.1.3.6.     Projected Opportunity in New Zealand

 

13.7.                 Encapsulated Cell Therapies for Neurological Disorders: Distribution by Indication

13.7.1.              Encapsulated Cell Therapies Market for Neurological Disorders: Ataxia Telangiectasia, till 2030

13.7.1.1.           EryDex System (EryDel)

13.7.1.1.1.        Target Patient Population

13.7.1.1.2.        Sales Forecast

13.7.1.1.3.        Geographical Distribution of Projected Opportunity

13.7.1.1.3.1.     Projected Opportunity in EU5

13.7.1.1.3.2.     Projected Opportunity in Rest of Europe

13.7.1.1.3.3.     Projected Opportunity in the US

13.7.1.1.3.4.     Projected Opportunity in Australia

13.7.1.1.3.5.     Projected Opportunity in India

13.7.1.1.3.6.     Projected Opportunity in Israel

13.7.1.1.3.7.     Projected Opportunity in Tunisia

 

13.7.2.              Encapsulated Cell Therapies Market for Neurological Disorders: Parkinson’s Disease, till 2030

13.7.2.1.           NTCELL® (Living Cell Technologies)

13.7.2.2.           Target Patient Population

13.7.2.2.1.        Sales Forecast

13.7.2.2.2.        Geographical Distribution of Projected Opportunity

13.7.2.2.2.1.     Projected Opportunity in New Zealand

13.7.2.2.2.2.     Projected Opportunity in the US

13.7.2.2.2.3.     Projected Opportunity in Australia

13.7.2.2.2.4.     Projected Opportunity in EU5

13.7.2.2.2.5.     Projected Opportunity in Rest of Europe

 

13.8.                 Encapsulated Cell Therapies for Oncological Disorders: Distribution by Indication

13.8.1.              Encapsulated Cell Therapies Market for Oncological Disorders: Pancreatic Cancer, till 2030

13.8.1.1.           GRASPA® (Erytech Pharma)

13.8.1.1.1.        Target Patient Population

13.8.1.1.2.        Sales Forecast

13.8.1.1.3.        Geographical Distribution of Projected Opportunity

13.8.1.1.3.1.     Projected Opportunity in EU5

13.8.1.1.3.2.     Projected Opportunity in Rest of Europe

13.8.1.1.3.3.     Projected Opportunity in the US

 

13.8.2.              Encapsulated Cell Therapies Market for Oncological Disorders: Non-Metastatic Pancreatic Cancer, till 2030

13.8.2.1.           Cell-in-a-Box® (PharmaCyte Biotech)

13.8.2.1.1.        Target Patient Population

13.8.2.1.2.        Sales Forecast

13.8.2.1.3.        Geographical Distribution of Projected Opportunity

13.8.2.1.3.1.     Projected Opportunity in the US

13.8.2.1.3.2.     Projected Opportunity in EU5

13.8.2.1.3.3.     Projected Opportunity of Cell-in-a-Box in Rest of Europe

 

13.8.3.              Encapsulated Cell Therapies Market for Oncological Disorders: Triple Negative Breast Cancer, till 2030

13.8.3.1.           GRASPA (Erytech Pharma)

13.8.3.1.1.        Target Patient Population

13.8.3.1.2.        Sales Forecast

13.8.3.1.3.        Geographical Distribution of Projected Opportunity

13.8.3.1.3.1.     Projected Opportunity in EU5

13.8.3.1.3.2.     Projected Opportunity in Rest of Europe

13.8.3.1.3.3.     Projected Opportunity in the US

 

13.8.4.              Encapsulated Cell Therapies Market for Oncological Disorders: Head and Neck Cancer, till 2030

13.8.4.1.           MVX-ONCO-1 (MaxiVAX)

13.8.4.1.1.        Target Patient Population

13.8.4.1.2.        Sales Forecast

13.8.4.1.3.        Geographical Distribution of Projected Opportunity

13.8.4.1.3.1.     Projected Opportunity in EU5

13.8.4.1.3.2.     Projected Opportunity in Rest of Europe

13.8.4.1.3.3.     Projected Opportunity in the US

 

  1. CONCLUSION

14.1.                 Cell-based Pharmacological Interventions are Characterized by Diverse Challenges, Most of which can be Mitigated using Various Encapsulation Strategies

14.2.                 The Pipeline Features Several Mid and Late Stage Encapsulated Therapy Products, Majority of which are intended for the Treatment of Metabolic Disorders

14.3.                 The Fragmented Developer Landscape Includes a Mix of Small and Mid-Sized Players; at Present, North America and Europe are Major Hubs of Development Activity

14.4.                 The Heightened Pace of Research in this Domain is Evident from the Rise in the Number of Patents Filed / Granted and the Clinical Studies Conducted in the Recent Years

14.5.                 Development Efforts in this Field have Drawn Significant Capital Investments from Private and Public Investors; this is Likely to Provide the Necessary Impetus to the Market’s Future Growth

14.6.                 Growth in Partnership Activity Reflects the Rising Interest of Industry Stakeholders; Most Agreements are Between Technology Providers and Cell Therapy Developers

14.7.                 Given the Increasing Number of Licensing Deals and the Expected Approval of Multiple Mid-Late Stage Candidates, the Market is Poised to Grow at a Significant Pace in the Coming Years

 

  1. EXECUTIVE INSIGHTS

15.1.                 Chapter Overview

15.2.                 Erytech Pharma

15.2.1.              Company Snapshot

15.2.2.              Interview Transcript: Alexander Scheer, Chief Scientific Officer

 

15.3.                 Defymed

15.3.1.              Company Snapshot

15.3.2.              Interview Transcript: Manuel Pires, Business Developer

 

15.4.                 Kadimastem

15.4.1.              Company Snapshot

15.4.2.              Interview Transcript: Michel Revel, Chief Scientist and Galit Mazooz-Perlmuter, Business Development Manager

 

15.5.                 Aterelix

15.5.1.              Company Snapshot

15.5.2.              Interview Transcript: Mick Mclean, Chief Executive Officer

 

15.6.                 Neurotech Pharmaceuticals

15.6.1.              Company Snapshot

15.6.2.              Interview Transcript: Quinton Oswald, Former President and Chief Executive Officer

 

15.7.                 Seraxis

15.7.1.              Company Snapshot

15.7.2.              Interview Transcript: William L Rust, Founder and Chief Executive Officer

 

15.8.                 Beta-O2 Technologies

15.8.1.              Company Snapshot

15.8.2.              Interview Transcript: Yuval Avni, Former Chief Executive Officer

 

  1. APPENDIX 1: TABULATED DATA

 

  1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact:

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com

The “Cell and Advanced Therapies Supply Chain Management Market, 2020-2030” report features an extensive study of the innovative software solutions that are being used to improve / optimize various supply chain-related processes of cell and advanced thera


Submitted 91 day(s) ago by Harry sins

 

 

To order this 510+ page report, please visit this link

 

Key Inclusions

  • A detailed assessment of the current market landscape, featuring a comprehensive list of over 160 technological platforms that are being used to manage the cell and advanced therapies supply chain, along with information on the different types of software systems (COP, EMS, IMS, LIMS, LMS, PMS, QMS, TTS, and others), their key specifications and benefits (chain of identity and custody, compatibility and integration, data management and analytics, regulatory compliance, reliability and security, scalability, software-as-a-service, traceability, user-friendliness, workflow management, and others), affiliated modes of deployment (cloud and on-premises), scale of management (small enterprise, mid-size enterprise and large enterprise), end users (biobanks, cell therapy labs, hospitals, research institutes, commercial organizations, and others), applications (ordering and scheduling, sample collection, manufacturing, logistics, and patient verification and treatment follow-up), regulatory certifications / accreditations (21 CFR Part 11, CLIA, FACT-JACIE, GAMP 5, GDPR, HIPAA, and others), and key support services offered (customization, installation / implementation, maintenance, training / technical support, upgradation, validation and testing, and others).
  • An insightful company competitiveness analysis, taking into consideration the supplier power (based on their employee base and years of experience in the industry) and portfolio-related parameters, such as number of software solutions offered, affiliated modes of deployment, scale of management, end users, applications, regulatory certifications / accreditations, support services offered, and key platform specifications and benefits.
  • Comprehensive profiles of industry players that are currently offering software solutions for supply chain management, featuring an overview of the company, its financial information (if available), and a detailed description of its software system(s). Each profile also includes a list of recent developments, highlighting the key achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth, in the foreseen future.
  • A detailed review of the cell and advanced therapies supply chain, offering insights on the processes associated with various stages, such as donor eligibility assessment, sample collection, manufacturing, logistics, and patient verification and treatment follow-up, along with information on cost requirements and existing opportunities for improvement in the supply chain management practices.
  • A qualitative assessment of the current and long-term needs of different stakeholders (patients, healthcare providers, collection centers, manufacturers, logistics service providers and regulators / payers) involved in the cell and advanced therapies supply chain, featuring a summary of the diverse needs and areas of concern, along with our opinion (based on past and prevalent trends) on how the industry is preparing to address such issues.
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies that are engaged in this field.
  • An analysis of the partnerships that have been established in the domain, in the period between 2014 and Q3 2019, covering software licensing agreements, mergers and acquisitions, product development agreements, product integration agreements, distribution agreements, asset purchase agreements, and other relevant deals.
  • A detailed analysis of the platform utilization use cases where aforementioned software systems were leveraged by various stakeholders in the domain, in the period between 2014 and Q3 2019, highlighting the ways in which companies have implemented such systems to improve / optimize various supply chain-related processes of cell and advanced therapies.
  • An in-depth analysis of the cost saving potential across various processes of the cell and advanced therapies supply chain that can be brought about by the implementation of bespoke and integrated technological solutions / software systems.
  • A case study on COPs, featuring insights on their key functions and implementation strategies, while also considering their strategic position and connectivity with other adjacent systems within the cell and advanced therapies supply chain. In addition, it provides a brief discussion on the growing popularity of COPs on the social media platform, Twitter.

 

The USD 1.5 billion (by 2030) financial opportunity within the cell and advanced therapies supply chain management market has been analysed across the following segments:

  • Application area
  • Sample collection and processing
  • Manufacturing
  • Logistics
  • Patient identification and treatment follow-up

 

  • Type of software solution
  • Cell orchestration platform
  • Enterprise manufacturing system
  • Inventory management system
  • Laboratory information management system
  • Logistics management system
  • Patient management system
  • Quality management system

 

  • Mode of Deployment
  • Cloud-based solution
  • On-premises solution

 

  • Scale of Operation
  • Clinical
  • Commercial

 

  • End user
  • Biobank
  • Cell therapy lab / commercial organization
  • Hospital / medical center
  • Research institute

 

  • Key geographical regions
  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

 

To request a sample pages, please visit this link       

 

Key Questions Answered

  • What are the trending software solutions for the management of cell and advanced therapies supply chain?
  • Who are the leading industry and non-industry players in this domain?
  • What are the key challenges faced by various stakeholders in this domain?
  • What kind of partnership models are commonly adopted by stakeholders in this industry?
  • Who are the key investors in this field?
  • What is the current and likely future cost saving opportunities associated with supply chain management solutions?
  • How is the current and future market opportunity likely to be distributed across key market segments and geographies?
  • What factors are likely to influence the evolution of this upcoming market?

 

You may also be interested in the following titles:

  1. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
  2. Stem Cell Therapy Contract Manufacturing Market, 2019-2030
  3. Cell and Gene Therapy CROs Market, 2018-2030

 

Contact:

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

 

 

Presently, over 160 innovative, software enabled systems are being used to efficiently manage and streamline various aspects of the complex supply chain of cell and advanced therapies


Submitted 91 day(s) ago by Harry sins

 

The cell and advanced therapies supply chain is complex, with several legacy challenges, such as those related to patient scheduling, resource planning, inventory management, and deliverable tracking. A number of innovative, software-enabled systems are available / under development to mitigate the aforementioned concerns and simplify the management of biopharmaceutical supply chains.

 

To order this 510+ page report, which features 185+ figures and 400+ tables, please visit this link

 

The USD 1.5 billion (by 2030) financial opportunity within the cell and advanced therapy supply chain management software solutions market has been analyzed across the following segments:

  • Application area
  • Sample collection and processing
  • Manufacturing
  • Logistics
  • Patient identification and treatment follow-up

 

  • Type of software solution
  • Cell orchestration platform
  • Enterprise manufacturing system
  • Inventory management system
  • Laboratory information management system
  • Logistics management system
  • Patient management system
  • Quality management system

 

  • Mode of Deployment
  • Cloud-based solution
  • On-premises solution

 

  • Scale of Operation
  • Clinical
  • Commercial

 

  • End user
  • Biobank
  • Cell therapy lab / commercial organization
  • Hospital / medical center
  • Research institute

 

  • Key geographical regions
  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

 

The Cell and Advanced Therapies Supply Chain Management Market: Focus on Technological Solutions (Cell Orchestration Platforms, Enterprise Manufacturing Systems, Inventory Management Systems, Laboratory Information Management Systems, Logistics Management Systems, Patient Management Systems, Quality Management Systems, Tracking & Tracing Systems, and Other Software), 2019-2030 report features the following companies, which we identified to be key players in this domain:

  • Be The Match BioTherapies®
  • Brooks Life Sciences
  • Clarkston Consulting
  • Cryoport
  • Haemonetics
  • Hypertrust Patient Data Care
  • Lykan Bioscience
  • MAK-SYSTEM
  • MasterControl
  • SAP
  • SAVSU Technologies
  • sedApta Group
  • Stafa Cellular Therapy
  • Title21 Health Solutions
  • TraceLink
  • TrakCel
  • Vineti

 

Table of Contents

 

  1. Preface

  2. Executive Summary

 

  1. Introduction

 

  1. Current Market Landscape

 

  1. Company Competitiveness Analysis

 

  1. Cell and Advanced Therapies Supply Chain Management: Company Profiles

 

  1. Supply Chain Orchestration Platform: Emerging Trends and Key Players

 

  1. Funding and Investment Analysis

 

  1. Partnerships and Collaborations

 

  1. Supply Chain Utilization Use Cases

 

  1. Stakeholder Needs Analysis

 

  1. Cost Savings Analysis

 

  1. Market Forecast

 

  1. Executive Insights

 

  1. Concluding Remarks

 

  1. Appendix 1: List of Additional Supply Chain Management Software Solutions

 

  1. Appendix 2: Tabulated Data

 

  1. Appendix 3: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/cell-therapies-supply-chain/260.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

 

 

Given the cost saving potential across different processes and operations, the cell and advanced therapies supply chain management market is projected to grow at an annualized rate of ~25% rapid till 2030


Submitted 91 day(s) ago by Harry sins

 

Roots Analysis has done a detailed study on Cell and Advanced Therapies Supply Chain Management Market: Focus on Technological Solutions (Cell Orchestration Platforms, Enterprise Manufacturing Systems, Inventory Management Systems, Laboratory Information Management Systems, Logistics Management Systems, Patient Management Systems, Quality Management Systems, Tracking & Tracing Systems, and Other Software), 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 510+ page report, which features 185+ figures and 400+ tables, please visit this link

 

Key Market Insights

  • Presently, over 160 innovative, software-enabled systems are being used to efficiently manage and streamline various aspects of the complex supply chain of cell and advanced therapies
  • Company involved in this domain are putting in significant efforts to develop advanced software solutions and also differentiate their offerings, from those of other industry players, in order to maintain a competitive edge
  • North America is the major hub of innovation in this field, serving as the base for companies of all sizes, which are primarily engaged in developing cloud-based solutions for diverse applications
  • The cell and advanced therapies market is characterized by an elaborate value chain, involving a multitude of processes and several stakeholders, each having a discrete set of priorities and requirements
  • Increase in partnership activity reflects the growing interest of stakeholders in this industry; over 50% of reported deals were established to deploy software solutions for enhancing visibility and supply chain performance
  • An analysis of recent activity on Twitter reveals the increasing interest and ongoing efforts of industry stakeholders in providing needle-to-needle traceability and supply chain orchestration solutions
  • Given their cost saving potential across different processes and operations, we expect the cell and advanced therapy supply chain solutions market to grow at an annualized rate of around 25% over the next decade
  • In the mid-long term, the projected opportunity is anticipated to be well distributed across various global regions, different end uses / applications and mode of deployment of various proprietary software solutions

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/cell-therapies-supply-chain/260.html

 

Table of Contents

 

  1. PREFACE

1.1.                  Scope of the Report

1.2.                  Research Methodology

1.3.                  Chapter Outlines


  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.                  Context and Background

3.2.                  An Introduction to Cell and Advanced Therapies

3.2.1.               Classification of Advanced Therapy Medicinal Products

3.2.2.               Current Market Landscape

 

3.3.                  Overview of Cell and Advanced Therapies Supply Chain

3.3.1.               Donor Eligibility and Selection

3.3.2.               Sample Collection

3.3.3.               Manufacturing

3.3.4.               Logistics

3.3.5.               Patient Verification and Treatment

 

3.3.6.               Challenges Associated with the Cell and Advanced Therapies Supply Chain

3.3.6.1.            Process Standardization

3.3.6.2.            Packaging and Shipping Qualification

3.3.6.3.            Validation of Storage Containers

3.3.6.4.            Process Qualification

3.3.6.5.            Chain of Custody Documentation

3.3.6.6.            Demand Forecastin

 

3.4.                  Software Solutions for Cell and Advanced Therapies Supply Chain Management

3.4.1.                Enterprise Manufacturing System

3.4.2.                Laboratory Information Management System

3.4.3.                Inventory Management System

3.4.4.                Quality Management System

3.4.5.                Logistics Management System

3.4.6.                Patient Management System

3.4.7.                Electronic Clinical Outcome Assessments System

3.4.8.                Supply Chain Orchestration Platfor

 

3.5.                  Growth Drivers and Roadblocks

3.6.                  Recent Developments and Upcoming Trends

3.6.1.                Blockchain Technology

3.6.2.                Internet of Things

3.6.3.                Augmented Reality

3.6.4.                Big Data Analytics

3.6.5.                Artificial Intelligence

 

  1. CURRENT MARKET LANDSCAPE

4.1.                  Chapter Overview

4.2.                  Cell and Advanced Therapies Supply Chain Management: Overall Market Landscape

4.2.1.                Analysis by Type of Software Solution

4.2.2.                Analysis by Key Specification and Benefits Offered

4.2.3.                Analysis by Application

4.2.4.                Analysis by Mode of Deployment

4.2.5.                Analysis by Scale of Management

4.2.6.                Analysis by Regulatory Certifications / Accreditations

4.2.7.                Analysis by End User

 

4.3.                  Cell and Advanced Therapies Supply Chain Management: Developer Landscape

4.3.1.                Analysis by Year of Establishment

4.3.2.                Analysis by Location of Headquarters

4.3.3.                Analysis by Company Size

4.3.4.                Analysis by Support Services Offered

4.3.5.                Leading Developers: Analysis by Number of Software Solutions

 

  1. COMPANY COMPETITIVENESS ANALYSIS

5.1.                  Chapter Overview

5.2.                  Methodology

5.3.                  Assumptions and Key Input Parameters

 

5.4.                  Competitiveness Analysis: Software Solution Providers

5.4.1.               COP Developers

5.4.2.               EMS Developers

5.4.3.               IMS Developers

5.4.4.               LIMS Developers

5.4.5.               LMS Developers

5.4.6.               PMS Developers

5.4.7.               QMS Developers

5.4.8.               TTS Developers

 

  1. CELL AND ADVANCED THERAPIES SUPPLY CHAIN MANAGEMENT: COMPANY PROFILES

6.1.                  Chapter Overview

6.2.                  Brooks Life Sciences

6.2.1.               Company Overview

6.2.2.               Supply Chain Management Software Solution Portfolio

6.2.3.               Recent Developments and Future Outlook

 

6.3.                  Cryoport

6.3.1.               Company Overview

6.3.2.               Financial Information

6.3.3.               Supply Chain Management Software Solution Portfolio

6.3.4.               Recent Developments and Future Outlook

 

6.4.                  MasterControl

6.4.1.               Company Overview

6.4.2.               Supply Chain Management Software Solution Portfolio

6.4.3.               Recent Developments and Future Outlook

 

6.5.                  SAP

6.5.1.               Company Overview

6.5.2.               Supply Chain Management Software Solution Portfolio

6.5.3.               Recent Developments and Future Outlook

 

6.6.                  Savsu Technologies

6.6.1.               Company Overview

6.6.2.               Financial Information

6.6.3.               Supply Chain Management Software Solution Portfolio

6.6.4.               Recent Development and Future Outlook

 

6.7.                  TraceLink

6.7.1.               Company Overview

6.7.2.               Financial Information

6.7.3.               Supply Chain Management Software Solution Portfolio

6.7.4.               Recent Developments and Future Outlook

 

  1. SUPPLY CHAIN ORCHESTRATION PLATFORM: EMERGING TRENDS AND KEY Players

7.1.                  Chapter Overview

7.2.                  Supply Chain Orchestration Platforms

7.2.1.                Key Functions of Supply Chain Orchestration Platforms

7.2.2.                Advantages of Supply Chain Orchestration Platforms

 

7.2.3.                Supply Chain Orchestration Platform Implementation Strategies

7.2.3.1.             Building the Required Foundation

7.2.3.2.             Incorporating an Appropriate Scheduling System

7.2.3.3.             Integration with Core Systems / Processe

 

7.3.                  Supply Chain Orchestration Platform: Social Media Trends

7.3.1.                Scope and Methodology

7.3.2.                Historical Trends in Volume of Tweets

7.3.3.                Popular Keyword

 

7.4.                  Key Industry Players

7.4.1.                Be The Match BioTherapies®

7.4.1.1.             Company Overview

7.4.1.2.             Financial Information

7.4.1.3.             MatchSource®: Software Description

7.4.1.4.             Recent Developments and Future Outloo

 

7.4.2.                Clarkston Consulting

7.4.2.1.             Company Overview

7.4.2.2.             Cell Therapy Orchestration Platform: Software Description

7.4.2.3.             Recent Developments and Future Outloo

 

7.4.3.               Haemonetics

7.4.3.1.            Company Overview

7.4.3.2.            Financial Information

7.4.3.3.            EdgeCell®: Software Description

7.4.3.4.            Recent Developments and Future Outlook

 

7.4.4.                Hypertrust Patient Data Care

7.4.4.1.             Company Overview

7.4.4.2.             Hypertrust X-Chain: Software Description

7.4.4.3.             Recent Developments and Future Outloo

 

7.4.5.                Lykan Bioscience

7.4.5.1.             Company Overview

7.4.5.2.             Unnamed Software: Software Description

7.4.5.3.             Recent Developments and Future Outlook

 

7.4.6.                MAK-SYSTEM

7.4.6.1.             Company Overview

7.4.6.2.             T.C.S.: Software Description

7.4.6.3.             Recent Developments and Future Outlook

 

7.4.7.                sedApta

7.4.7.1.             Company Overview

7.4.7.2.             O.S.A.: Software Description

7.4.7.3.             Recent Developments and Future Outlook

 

7.4.8.                Stafa Cellular Therapy

7.4.8.1.             Company Overview

7.4.8.2.             Stafa Cellular Therapy Lab: Software Description

7.4.8.3.             Recent Developments and Future Outlook

 

7.4.9.               Title 21 Health Solutions

7.4.9.1.            Company Overview

7.4.9.2.            Cell Therapy Software: Software Description

7.4.9.3.            Recent Developments and Future Outlook

 

7.4.10.              TrakCel

7.4.10.1.           Company Overview

7.4.10.2.           Financial Information

7.4.10.3.           Cell Orchestration Platform: Software Description

7.4.10.4.           Recent Developments and Future Outlook

 

7.4.11.              Vineti

7.4.11.1.           Company Overview

7.4.11.2.           Financial Information

7.4.11.3.           Personalized Therapy Management Platform: Software Description

7.4.11.4.           Recent Developments and Future Outlook

 

  1. FUNDING AND INVESTMENT ANALYSIS

8.1.                  Chapter Overview

8.2.                  Types of Funding

8.3.                  Cell and Advanced Therapies Supply Chain Management: Funding and Investment Analysis

8.3.1.               Analysis by Number of Funding Instances

8.3.2.               Analysis by Amount Invested

8.3.3.               Analysis by Type of Funding

8.3.4.               Analysis by Number of Funding Instances and Amount Invested across Different Software Solutions

8.3.5.               Most Active Players: Analysis by Number of Funding Instances

8.3.6.               Most Active Investors: Analysis by Number of Funding Instances

8.3.7.               Geographical Analysis by Amount Invested

8.4.                  Concluding Remarks

 

  1. PARTNERSHIPS AND COLLABORATIONS

9.1.                  Chapter Overview

9.2.                  Partnership Models

9.3.                  Cell and Advanced Therapies Supply Chain Management: Recent Collaborations and Partnerships

9.3.1.               Analysis by Year of Partnership

9.3.2.               Analysis by Type of Partnership

9.3.3.               Partner’s Focus Area

9.3.3.1.             Analysis by Partner’s Focus Area

9.3.3.2.            Analysis by Type of Platform and Partner’s Focus Area

9.3.3.3.            Analysis by Type of Partnership Model and Partner’s Focus Area

 

9.3.4.               Software Solution Analysis

9.3.4.1.            Analysis by Type of Software Solutions

9.3.4.2.            Analysis by Type of Platform and Partnership Model

 

9.3.5.               Most Active Players: Analysis by Number of Partnerships

9.3.6.               Geographical Analysis

9.3.6.1.            Most Active Players

9.3.6.2.            Intercontinental and Intracontinental Agreements

 

  1. SUPPLY CHAIN UTILIZATION USE CASES

10.1.                Chapter Overview

10.2.                Cell and Advanced Therapies Supply Chain Management: Recent Platform Utilization Use Cases

10.2.1.             Analysis by Year of Utilization

10.2.2.             Analysis by Type of Partner

10.2.2.1.           Most Active Users: Distribution by Number of Platform Utilization Instances

10.2.2.2.           Geographical Distribution of Users

 

10.2.3.             Analysis by Type of Software Solution

10.2.4.             Most Active Players: Analysis by Number of Platform Utilization Agreements

10.2.5.             Most Active Players: Regional Analysis by Number of Platform Utilization Agreements

10.2.5.1.           Regional Distribution by Type of Software Solutions

10.2.5.2.           Intercontinental and Intracontinental Agreements

 

  1. STAKEHOLDER NEEDS ANALYSIS

11.1.                Chapter Overview

11.2.                Cell and Advanced Therapies Supply Chain Management: Needs of Different Stakeholders

11.2.1.             Comparison of Stakeholder Needs

 

  1. COST SAVINGS ANALYSIS

12.1.                Chapter Overview

12.2.                Key Assumptions and Methodology

 

12.3.                Overall Cost Saving Potential of Supply Chain Management Software Solutions, 2019-2030

12.3.1.             Cost Saving Potential in Sample Collection and Processing, 2019-2030

12.3.2.             Cost Saving Potential in Manufacturing, 2019-2030

12.3.3.              Cost Saving Potential in Logistics, 2019-2030

12.3.4.             Cost Saving Potential in Patient Verification and Treatment Follow-up, 2019-2030

 

  1. MARKET FORECAST

13.1.                Chapter Overview

13.2.                Key Assumptions and Forecast Methodology

 

13.3.                Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, 2019-2030

13.3.1.             Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application

13.3.1.1.           Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection and Processing, 2019-2030

13.3.1.2.           Cell and Advanced Therapies Supply Chain Management Solutions Market for, Manufacturing, 2019-2030

13.3.1.3.           Cell and Advanced Therapies Supply Chain Management Solutions Market for, Logistics, 2019-2030

13.3.1.4.           Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030

 

13.3.2.             Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User

13.3.2.1.           Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, 2019-2030

13.3.2.2.           Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs / Commercial Organizations, 2019-2030

13.3.2.3.           Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals / Medical Centers, 2019-2030

13.3.2.4.           Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, 2019-2030

 

13.3.3.             Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution

13.3.3.1.           Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030

13.3.3.2.           Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030

13.3.3.3.           Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030

13.3.3.4.           Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030

13.3.3.5.           Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030

13.3.3.6.           Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030

13.3.3.7.           Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030

 

13.3.4.             Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment

13.3.4.1.           Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, 2019-2030

13.3.4.2.           Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, 2019-2030

 

13.3.5.             Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Scale of Operation

13.3.5.1.           Cell and Advanced Therapies Supply Chain Management Market for Clinical Therapies, 2019-2030

13.3.5.2.           Cell and Advanced Therapies Supply Chain Management Market for Commercial Therapies, 2019-2030

 

13.3.6.             Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography

13.3.6.1.           Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, 2019-2030

13.3.6.2.           Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, 2019-2030

13.3.6.3.           Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, 2019-2030

13.3.6.4.           Cell and Advanced Therapies Supply Chain Management Solutions Market in Rest of the World, 2019-2030

 

13.4.                Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Type of Software Solution and Mode of Deployment

13.4.1.             Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection and Processing, 2019-2030

13.4.1.1.           Cell Orchestration Platforms Market for Sample Collection and Processing, 2019-2030

13.4.1.1.1.        Cell Orchestration Platforms Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030

13.4.1.1.2.        Cell Orchestration Platforms Market for Sample Collection and Processing: On-premises Solutions, 2019-2030

 

13.4.1.2.           Enterprise Manufacturing Systems Market for Sample Collection and Processing, 2019-2030

13.4.1.2.1.        Enterprise Manufacturing Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030

13.4.1.2.2.        Enterprise Manufacturing Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030

 

13.4.1.3.           Inventory Management Systems Market for Sample Collection and Processing, 2019-2030

13.4.1.3.1.        Inventory Management Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030

13.4.1.3.2.        Inventory Management Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030

 

13.4.1.4.           Laboratory Information Management Systems Market for Sample Collection and Processing, 2019-2030

13.4.1.4.1.        Laboratory Information Management Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030

13.4.1.4.2.        Laboratory Information Management Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030

 

13.4.1.5.           Logistics Management Systems Market for Sample Collection and Processing, 2019-2030

13.4.1.5.1.        Logistics Management Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030

13.4.1.5.2.        Logistics Management Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030

 

13.4.1.6.           Patient Management Systems Market for Sample Collection and Processing, 2019-2030

13.4.1.6.1.        Patient Management Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030

13.4.1.6.2.        Patient Management Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030

 

13.4.1.7.           Quality Management Systems Market for Sample Collection and Processing, 2019-2030

13.4.1.7.1.        Quality Management Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030

13.4.1.7.2.        Quality Management Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030        

 

13.4.2.             Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, 2019-2030

13.4.2.1.           Cell Orchestration Platforms Systems Market for Manufacturing, 2019-2030

13.4.2.1.1.        Cell Orchestration Platforms Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030

13.4.2.1.2.        Cell Orchestration Platforms Systems Market for Manufacturing: On-premises Solutions, 2019-2030

 

13.4.2.2.           Enterprise Manufacturing Systems Market for Manufacturing, 2019-2030

13.4.2.2.1.        Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030

13.4.2.2.2.        Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, 2019-2030

 

13.4.2.3.           Inventory Management Systems Market for Manufacturing, 2019-2030

13.4.2.3.1.        Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030

13.4.2.3.2.        Inventory Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030

 

13.4.2.4.           Laboratory Information Management Systems Market for Manufacturing, 2019-2030

13.4.2.4.1.        Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030

13.4.2.4.2.        Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030

 

13.4.2.5.           Logistics Management Systems Market for Manufacturing, 2019-2030

13.4.2.5.1.        Logistics Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030

13.4.2.5.2.        Logistics Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030

 

13.4.2.6.           Patient Management Systems Market for Manufacturing, 2019-2030

13.4.2.6.1.        Patient Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030

13.4.2.6.2.        Patient Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030

 

13.4.2.7.           Quality Management Systems Market for Manufacturing, 2019-2030

13.4.2.7.1.        Quality Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030

13.4.2.7.2.        Quality Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030

 

13.4.3.             Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, 2019-2030

13.4.3.1.           Cell Orchestration Platforms Market for Logistics, 2019-2030

13.4.3.1.1.        Cell Orchestration Platforms Market for Logistics: Cloud-based Solutions, 2019-2030

13.4.3.1.2.        Cell Orchestration Platforms Market for Logistics: On-premises Solutions, 2019-2030

 

13.4.3.2.           Enterprise Manufacturing Systems Market for Logistics, 2019-2030

13.4.3.2.1.        Enterprise Manufacturing Systems Market for Logistics: Cloud-based Solutions, 2019-2030

13.4.3.2.2.        Enterprise Manufacturing Systems Market for Logistics: On-premises Solutions, 2019-2030

 

13.4.3.3.           Inventory Management Systems Market for Logistics, 2019-2030

13.4.3.3.1.        Inventory Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030

13.4.3.3.2.        Inventory Management Systems Market for Logistics: On-premises Solutions, 2019-2030

 

13.4.3.4.           Laboratory Information Management Systems Market for Logistics, 2019-2030

13.4.3.4.1.        Laboratory Information Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030

13.4.3.4.2.        Laboratory Information Management Systems Market for Logistics: On-premises Solutions, 2019-2030

 

13.4.3.5.           Logistics Management Systems Market for Logistics, 2019-2030

13.4.3.5.1.        Logistics Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030

13.4.3.5.2.        Logistics Management Systems Market for Logistics: On-premises Solutions, 2019-2030

 

13.4.3.6.           Patient Management Systems Market for Logistics, 2019-2030

13.4.3.6.1.        Patient Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030

13.4.3.6.2.        Patient Management Systems Market for Logistics: On-premises Solutions, 2019-2030

 

13.4.4.             Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030

13.4.4.1.           Cell Orchestration Platforms Market for Patient Verification and Treatment Follow-up, 2019-2030

13.4.4.1.1.        Cell Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030

13.4.4.1.2.        Cell Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030

 

13.4.4.2.           Inventory Management Systems Market for Patient Verification and Treatment Follow-up, 2019-2030

13.4.4.2.1.        Inventory Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030

13.4.4.2.2.        Inventory Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030

 

13.4.4.3.           Patient Management Systems Market for Patient Verification and Treatment Follow-up, 2019-2030

13.4.4.3.1.        Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030

13.4.4.3.2.        Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030

 

  1. EXECUTIVE INSIGHTS

14.1.                 Chapter Overview

14.2.                 Thermo Fisher Scientific

14.2.1.              Company Snapshot

14.2.2.              Interview Transcript: Bryan Poltilove, Former General Manager, Cell and Gene Therapy

 

14.3.                 Cell and Gene Therapy Catapult

14.3.1.              Company Snapshot

14.3.2.              Interview Transcript: Jacqueline Barry, Chief Clinical Officer

 

14.4.                 McKesson

14.4.1.              Company Snapshot

14.4.2.              Interview Transcript: Divya Iyer, Senior Director, Corporate Strategy and Business Development, and Jill Maddux, Director, Cell and Gene Therapy Product Strategy

 

14.5.                 TrakCel

14.5.1.              Company Snapshot

14.5.2.              Interview Transcript: Martin Lamb, Former Chief Business Officer

 

  1. CONCLUDING REMARKS

15.1.                 Chapter Overview

15.2.                 Key Takeaways

 

  1. APPENDIX 1: LIST OF ADDITIONAL SUPPLY CHAIN MANAGEMENT SOFTWARE SOLUTIONS

 

  1. APPENDIX 2: TABULATED DATA

 

  1. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Companion Diagnostics Development Services Market, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of diagnostic development services over the next decade. It features an i


Submitted 92 day(s) ago by Harry sins

To order this detailed 320+ page report, please visit this link

 

Key Inclusions

  • A detailed assessment of the current market landscape of companies offering companion diagnostics services, including information on the type of services offered, type of analytical technique used and regulatory certifications / accreditations, and other company-specific details (such as year of establishment, company size and geographical location).
  • Tabulated profiles of companion diagnostics service providers (shortlisted on the basis of the number of services offered), featuring an overview of the company, its financial information (if available), and companion diagnostics-related service portfolio details. In addition, each profile includes a list of the likely strategies that may be adopted by these players to support future growth.
  • An analysis of the partnerships and collaborations pertaining to companion diagnostics services from 2017 to 2019, featuring a detailed set of analyses based on various parameters, such as the type of partnership, year of partnership, analytical technique used and the most active players.
  • A list of stakeholders generated based on a detailed analysis of a set of relevant parameters (namely number of clinical trials sponsored by a developer and the time to market for proprietary personalized medicine products), which are anticipated to partner with companion diagnostics services providers in the foreseen future.
  • A detailed competitiveness analysis of companion diagnostics services providers, taking into consideration the supplier power (based on the year of establishment of developer) and key specifications, such as portfolio strength, type of available technology platform, number of deals signed between 2017-2019.
  • A comparative analysis of the needs of different stakeholders (drug developers, diagnostic developers, testing laboratories, physicians, payers and patients) involved in this domain.
  • A discussion on various steps of the development operations, namely research and development, clinical assessment of the product, manufacturing and assembly, payer negotiation and marketing / sales activities, of a companion diagnostic and the cost requirements across each of the aforementioned stages.
  • An analysis of completed, ongoing and planned clinical trials featuring disease-specific biomarkers. The analysis highlights the key trends associated with these clinical studies across various parameters, such as trial start year, trial status, phase of development, key indications, type of therapy, biomarkers evaluated, enrolled patient population and regional distribution of trials.
  • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
  • Type of Services
  • Feasibility Studies
  • Assay Development
  • Analytical Validation
  • Clinical Validation
  • Manufacturing
  • Type of Analytical Technique
  • in situ hybridization / Immunohistochemistry
  • Next Generation Sequencing
  • Polymerase Chain Reaction
  • Others
  • Key Geographical Region 
  • North America
  • Europe
  • Asia-Pacific and the Rest of World 

 

Transcripts of interviews held with the following senior level representatives of stakeholder companies

  • Anton Iliuk (President, Chief Technology Officer Tymora Analytical Operations)
  • Paul Kortschak (Senior Vice President, Novodiax)
  • Pablo Ortiz (Chief Executive Officer, OWL Metabolomics)
  • Lawrence M. Weiss (Chief Scientific Officer, NeoGenomics Laboratories)

 

To request sample pages, please visit this link

 

Key Questions Answered

  • Who are the key players that provide services for the development of companion diagnostics?
  • What kind of partnership models are commonly adopted by stakeholders in this domain?
  • What are the various initiatives undertaken by big pharma players in this domain?
  • What are cost requirements across each of the development stages of a companion diagnostics test?
  • Which developer companies are likely to partner with service provider entities in the foreseen future?
  • What are the current and long-term needs of different stakeholders involved in this domain?
  • How is the current and future market opportunity likely to be distributed across key market segments?

 

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

Contact Us

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Over 180 companies from different regions across the globe presently claim to provide services for the development of companion diagnostic tests, claims Roots Analysis


Submitted 92 day(s) ago by Harry sins

 

It is estimated that around 80% of innovator companies rely on external companion diagnostic developers, mostly owing to the lack of the required in-house expertise. On the other hand, there are numerous contract service providers, offering vast portfolios of services for diagnostic test / assay development. Such companies are known to possess extensive technical knowledge, and experience in working with cutting-edge analytical tools and technologies, such as in situ hybridization (ISH), immunohistochemistry (IHC), next generation sequencing (NGS), polymerase chain reaction (PCR).

 

To  order this 320+ page report, which features 120+ figures and 115+ tables, please visit this link

 

The USD 800+ million (by 2030) financial opportunity within the companion diagnostics development services market has been analysed across the following segments:

  • Type of Service Offered
  • Feasibility Studies
  • Assay Development
  • Analytical Validation
  • Clinical Validation

 

  • Type of Assay Technique Used
  • in situ hybridization / Immunohistochemistry
  • Next Generation Sequencing
  • Polymerase Chain Reaction
  • Others

 

  • Key geographical regions
  • North America
  • Europe
  • Asia Pacific

 

 

The report features inputs from eminent industry stakeholders, according to whom the development of companion diagnostics is largely outsourced, owing to the exorbitant costs associated with the setting-up of in-house expertise / capabilities. The report includes detailed transcripts of discussions held with the following experts:

  • Anton Iliuk (President and Chief Technology Officer, Tymora Analytica)
  • Paul Kortschak (Senior Vice President, Novodiax)
  • Pablo Ortiz (Chief Executive officer, OWL Metabolomics)
  • Lawrence M. Weiss (Chief Scientific Officer, NeoGenomics Laboratories)

 

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Market Landscape

  4. Company Profiles

 

  1. Partnerships and Collaborations

  2. Likely Partner Analysis

  3. Company Competitiveness Analysis

  4. Stakeholder Needs Analysis

  5. Value Chain Analysis

 

  1. Clinical Research on Cancer Biomarkers: Big Pharma Perspective

 

  1. Market Forecast And Opportunity Analysis

 

  1. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com  

 

The Companion Diagnostics Development Services Market is projected to grow at an annualized rate of ~5%, till 2030


Submitted 92 day(s) ago by Harry sins

 

Roots Analysis has done a detailed report on Companion Diagnostics Development Services Market covering key aspects of the industry and identifying future growth opportunities

 

 

To order this 320+ page report, which features 120+ figures and 115+ tables, please visit this link

 

Key Market Insights

  • Over 180 companies from different regions across the globe presently claim to provide services for the development of companion diagnostic tests
  • Currently, a variety of services are available across the entire diagnostics development supply chain, including assays based on a wide range of analytical techniques, especially in the developed geographies
  • Numerous pharmaceutical players are actively seeking to enter into partnership with companion diagnostics service providers, in order to leverage the latter’s expertise in this field
  • The rise in interest in this field is reflected in the number of partnerships established in the recent past, involving both international and indigenous stakeholders, and focused on a variety of end objectives
  • In order to achieve an edge over the contemporary competition, companies engaged in this domain are increasingly focusing on the integration of advanced service offerings in their respective portfolios
  • The value chain involves drug and diagnostics developers, service providers, along with other important stakeholders, each having a discrete set of priorities and requirements
  • Given the growing demand for precision medicine, the companion diagnostics services market is expected to witness a double digit growth; the opportunity is likely to be distributed across different regions and techniques
  • In the long-term, growth in the market is anticipated to be driven by the clinical studies based on novel tumor markers, which have been identified as promising biological targets for development of companion diagnostics

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html

 

Table of Contents

 

  1. PREFACE
    1.1. Scope of the Report
    1.2.      Research Methodology
    1.3.      Chapter Outlines

    2.         EXECUTIVE SUMMARY

  2. INTRODUCTION

3.1.      Chapter Overview

3.2.      Evolution of Personalized Medicine

 

3.3.      Overview of Companion Diagnostics

3.3.1.    Development of Companion Diagnostics

3.3.2.    Analytical Techniques Used in Companion Diagnostic Tests

3.3.2.1. Immunohistochemistry

3.3.2.2. In situ Hybridization

3.3.2.3. Polymerase Chain Reaction

3.3.2.4. DNA Sequencing / Next Generation Sequencing

3.3.3.    Advantages of Companion Diagnostics

3.4.      Applications of Companion Diagnostics across Different Therapeutic Areas

3.4.1.    Oncology

3.4.2.    Infectious Diseases

3.4.3.    Neurological Disorders

3.5.      Regulatory Review and Approval Process for Companion Diagnostics

3.6.      Existing Challenges

3.7.      Future Roadmap

  1. MARKET LANDSCAPE

4.1.      Chapter Overview

4.2.      Companion Diagnostics Service Providers: Overall Market Landscape

4.2.1     Analysis by Type of Service Offered

4.2.2.    Analysis by Type of Analytical Technique

4.2.3.    Analysis by Regulatory Accreditation / Certification

 

4.3.      Companion Diagnostics Service Providers: Developer Landscape

4.3.1     Analysis by Year of Establishment

4.3.2     Analysis by Company Size

4.3.3     Analysis by Geographical Location

4.3.4     Grid Representation: Analysis by Type of Service Offered, Company Size, and Geographical Location

4.3.5     World Map Representation: Analysis by Geography

 

  1. COMPANY PROFILES

5.1.      Chapter Overview

 

5.2.      Key Players in North America

5.2.1.    Asuragen

5.2.1.1. Recent Developments and Future Outlook

 

5.2.2.    Covance

5.2.2.1. Recent Developments and Future Outlook

 

5.2.3.    Geneuity

5.2.3.1. Recent Developments and Future Outlook

 

5.2.4.    MD Biosciences

5.2.4.1. Recent Developments and Future Outlook

 

5.2.5.    ResearchDx

5.2.5.1. Recent Developments and Future Outlook

 

5.3.      Players in Europe

5.3.1.    Almac Diagnostic Services

5.3.1.1. Recent Developments and Future Outlook

 

5.3.2.    Leica Biosystems

5.3.2.1. Recent Developments and Future Outlook

 

5.3.3.    R-Biopharm

5.3.3.1. Recent Developments and Future Outlook

 

5.3.4.    Tepnel Pharma Services

5.3.4.1. Recent Developments and Future Outlook

 

5.4.      Key Players in Asia-Pacific

5.4.1.    BARD1 Life Sciences

5.4.1.1. Recent Developments and Future Outlook

 

5.4.2.    BioMarCare Technologies

5.4.2.1. Recent Developments and Future Outlook

 

5.4.3.    Gencurix

5.4.3.1. Recent Developments and Future Outlook

 

5.4.4.    Macrogen

5.4.4.1. Recent Developments and Future Outlook

           

  1. PARTNERSHIPS AND COLLABORATIONS

6.1       Chapter Overview

6.2       Partnership Models

6.3       List of Partnerships and Collaborations

6.3.1     Analysis by Year of Partnership

6.3.2     Analysis by Type of Partnership

6.3.3     Analysis by Type of Analytical Technique

6.3.4     Analysis by Type of Therapeutic Area

6.3.5     Analysis by Year of Partnership and Type of Partner

6.3.6     Analysis by Type of Partnership and Type of Partner

6.3.7     Most Active Players: Analysis by Number of Partnerships

6.3.8     Popular Analytical Techniques: Analysis by Number of Partnerships

6.3.9     Regional Analysis

6.3.10   Intercontinental and Intracontinental Agreements

 

  1. LIKELY PARTNER ANALYSIS

7.1.      Chapter Overview

7.2.      Scope and Methodology

7.3.      Scoring Criteria and Key Assumptions

7.4.      Likely Partners for Companion Diagnostics Service Providers: Alzheimer’s Disease

7.4.1.    Companies Working on the Amyloid Beta Biomarker

7.4.1.1. World Map Representation: Amyloid Beta Biomarker Focused Clinical Trials

 

7.4.2.    Companies Working on the Tau Biomarker

7.4.2.1. World Map Representation: Tau Biomarker Focused Clinical Trials

 

7.5.      Likely Partners for Companion Diagnostics Service Providers: Breast Cancer

7.5.1.    Companies Working on the BRCA Biomarker

7.5.1.1. World Map Representation: BRCA Biomarker Focused Clinical Trials

 

7.5.2.    Companies Working on the HER Biomarker

7.5.2.1. World Map Representation: HER Biomarker Focused Clinical Trials

 

7.5.3.    Companies Working on the HR Biomarker

7.5.3.1. World Map Representation: HR Biomarker Focused Clinical Trials

 

7.5.4.    Companies Working on the PD-L1 Biomarker

7.5.4.1. World Map Representation: PD-L1 Biomarker Focused Clinical Trials

 

7.6.      Likely Partners for Companion Diagnostics Service Providers: Colorectal Cancer

7.6.1.    Companies Working on the BRAF Biomarker

7.6.1.1. World Map Representation: BRAF Biomarker Focused Clinical Trials

 

7.6.2.    Companies Working on the EGFR Biomarker

7.6.2.1. World Map Representation: EGFR Biomarker Focused Clinical Trials

 

7.6.3.    Companies Working on the KRAS Biomarker

7.6.3.1. World Map Representation: KRAS Biomarker Focused Clinical Trials

 

7.6.4.    Companies Working on the MSI Biomarker

7.6.4.1. World Map Representation: MSI Biomarker Focused Clinical Trials

 

7.6.5.    Companies Working on the NRAS Biomarker

7.6.5.1. World Map Representation: NRAS Biomarker Focused Clinical Trials

 

7.7.      Likely Partners for Companion Diagnostic Service Providers: HIV

7.7.1.    Companies Working on the CCR5 Biomarker

7.7.1.1. World Map Representation: CCR5 Biomarker Focused Clinical Trials

 

7.8.      Likely Partners for Companion Diagnostics Service Providers: Lung Cancer

7.8.1.    Companies Working on the ALK Biomarker

7.8.1.1. World Map Representation: ALK Biomarker Focused Clinical Trials

 

7.8.2.    Companies Working on the EGFR Biomarker

7.8.2.1. World Map Representation: EGFR Biomarker Focused Clinical Trials

 

7.8.3.    Companies Working on the PD-L1 Biomarker

7.8.3.1. World Map Representation: PD-L1 Biomarker Focused Clinical Trials

 

7.8.4.    Companies Working on the ROS Biomarker

7.8.4.1. World Map Representation: ROS Biomarker Focused Clinical Trials

 

7.9.      Likely Partners for Companion Diagnostics Service Providers: NASH / NAFLD

7.9.1.    Companies Working on the AST Biomarker

7.9.1.1. World Map Representation: AST Biomarker Focused Clinical Trials

 

7.10.     Likely Partners for Companion Diagnostics Service Providers: Ovarian Cancer

7.10.1.  Companies Working on the BRCA Biomarker

7.10.1.1. World Map Representation: BRCA Biomarker Focused Clinical Trials

 

7.10.2.  Companies Working on the CA-125 Biomarker

7.10.2.1. World Map Representation: CA-125 Biomarker Focused Clinical Trials

7.11.     Likely Partners for Companion Diagnostics Service Providers: Prostate Cancer

7.11.1.  Companies Working on the PTEN Biomarker

7.11.1.1. World Map Representation: PTEN Biomarker Focused Clinical Trials

 

  1. COMPANY COMPETITIVENESS ANALYSIS

8.1       Chapter Overview

8.2       Methodology

8.3       Assumptions and Key Parameters

8.4       Company Competitiveness Analysis

8.4.1     Companion Diagnostics Service Providers based in North America

8.4.2     Companion Diagnostics Service Providers based in Europe

8.4.3     Companion Diagnostics Service Providers based in Asia Pacific / RoW

 

  1. STAKEHOLDER NEEDS ANALYSIS

9.1.      Chapter Overview

9.2.      Companion Diagnostics: Needs of Different Stakeholders

9.3.      Comparison of Needs of Various Stakeholders

9.3.1.    Needs of Drug Developers

9.3.2.    Needs of Companion Diagnostics Developers

9.3.3.    Needs of Regulatory Authorities

9.3.4.    Needs of Testing Laboratories

9.3.5.    Needs of Payers / Insurance Providers

9.3.6.    Needs of Physicians

9.3.7.    Needs of Patients

 

  1. VALUE CHAIN ANALYSIS

10.1.     Chapter Overview

10.2.     Companion Diagnostics Value Chain: Cost Distribution

10.2.1.  Research and Product Development

10.2.2. Manufacturing and Assembly

10.2.3.  Clinical Trials, FDA Approval and Other Administrative Tasks

10.2.4.  Payer Negotiation and KOL Engagement

10.2.5.  Marketing and Sales

 

10.3.     Companion Diagnostics Development Operations: Key Cost Contributors

10.4.     Companion Diagnostics Co-Development Operations: Key Cost Contributors

 

  1. CLINICAL RESEARCH ON CANCER BIOMARKERS: BIG PHARMA PERSPECTIVE

11.1.     Chapter Overview

11.2.     Methodology

11.3.     Clinical Trial Analysis

11.3.1.  List of Likely Drug Candidates for IVD Developers

 

11.4.     Cumulative Distribution of Biomarker Focused Trials by Registration Year, 2016-2019

11.4.1.  Analysis of Trials for Most Popular Biomarkers

11.4.2.  Analysis of Trials for Moderately Popular Biomarkers

11.4.3.  Analysis of Trials for Less Popular / Preliminary Stage Biomarkers

11.4.4.  Other Emerging Biomarkers: Word Cloud

11.4.5.  Cumulative Distribution of Trials of the Most Popular Biomarkers by Registration Year

11.4.6.  Cumulative Distribution of Trials of the Moderately Popular Biomarkers by Registration   Year

11.4.7.  Cumulative Distribution of Trials of the Less Popular Biomarkers by Registration Year

 

11.5.     Analysis of Biomarker Focused Trials for Most Popular Indications

11.5.1.  Analysis of Trials for Moderately Popular Indications

11.5.2.  Analysis of Trials for Less Popular and Other Indications

11.5.3.  Other Emerging Indications: Word Cloud

11.5.4.  Cumulative Distribution of Trials of the Most Popular Indications by Registration Year

11.5.5.  Cumulative Distribution of Trials of the Moderately Popular Indications by Registration Year

11.5.6.  Cumulative Distribution of Trials of the Less Popular / Preliminary Stage Indications by Registration Year

 

11.6.     Analysis of Biomarker Focused Trials by Phase of Development

11.6.1.  Analysis of Trials of the Most Popular Biomarkers

11.6.2.  Analysis of Trials of the Moderately Popular Biomarkers

11.6.3.  Analysis of Trials of the Less Popular and Other Biomarkers

11.6.4.  Analysis of Trials of the Most Popular Indications

11.6.5.  Analysis of Trials of the Moderately Popular Indications

11.6.6.  Analysis of Trials of the Less Popular and Other Indications

 

11.7.     Analysis of Biomarker Focused Trials by Sponsor

11.7.1.  Analysis of Trials of the Most Popular Biomarkers

11.7.2.  Analysis of Trials of the Moderately Popular Biomarkers

11.7.3.  Analysis of Trials of the Most Popular Indications

11.7.4.  Analysis of Trials of the Moderately Popular Indications

 

11.8.     Analysis of Biomarker Focused Trials by Recruitment Status

11.9.     Analysis of Biomarker Focused Trials by Therapy Design

 

11.10.   Analysis of Biomarker Focused Trials by Geography

11.10.1. Analysis of Trials by Phase of Development and Recruitment Status

 

11.11.   Clinical Trials Summary: Analysis of Biomarker Focused Trials by Most Popular Indications

11.12.   Clinical Trials Summary: Analysis of Biomarker Focused Trials by Moderately Popular Indications

11.13.   Clinical Trials Summary: Analysis of Biomarker Focused Trials by Preliminary Stage Indications

 

  1. MARKET FORECAST AND OPPORTUNITY ANALYSIS

12.1      Chapter Overview

12.2.     Key Assumptions and Forecast Methodology

12.3.     Global Companion Diagnostics Services Market, 2020-2030  

12.3.1.  Global Companion Diagnostics Services Market: Distribution by Type of Service Offered, 2020 2030

12.3.2.  Global Companion Diagnostics Services Market: Distribution by Type of Analytical Technique, 2020-2030

12.3.3.  Global Companion Diagnostics Services Market: Distribution by Region, 2020-2030

12.4.     Companion Diagnostics Services Market in North America, 2020-2030

12.4.1.  Companion Diagnostics Services Market in the North America: Distribution by Type of Service Offered, 2020-2030

12.4.2. Companion Diagnostics Services Market in the North America: Distribution by Type of Analytical Technique, 2020-2030

 

12.5.     Companion Diagnostics Services Market in Europe, 2020-2030

12.5.1.  Companion Diagnostics Services Market in Europe: Distribution by Type of Service Offered, 2020-2030

12.5.2.  Companion Diagnostics Services Market in Europe: Distribution by Type of Analytical Technique, 2020-2030

 

12.6.     Companion Diagnostics Services Market in Asia Pacific and Rest of the World, 2020-2030

12.6.1.  Companion Diagnostics Services Market in Asia Pacific and Rest of the World: Distribution by Type of Service Offered, 2020-2030

12.6.2.  Companion Diagnostics Services Market in Asia Pacific and Rest of the World: Distribution by Type of Analytical Technique, 2020-2030

 

  1. EXECUTIVE INSIGHTS

13.1.     Chapter Overview

 

13.2.     Tymora Analytical Operations

13.2.1.  Company Snapshot

13.2.2.  Anton Iliuk (President, Chief Technology Officer), Tymora Analytical Operations

 

13.3.     Novodiax

13.3.1.  Company Snapshot

13.3.2.  Paul Kortschak (Senior Vice President, Novodiax)

 

13.4.     OWL Metabolomics

13.4.1.  Company Snapshot

13.4.2.  Pablo Ortiz (Chief Executive Officer, OWL Metabolomics)

 

13.5.     NeoGenomics Laboratories

13.5.1.  Company Snapshot

13.5.2.  Lawrence M. Weiss (Chief Scientific Officer, NeoGenomics Laboratories)

 

  1. CONCLUDING REMARKS

 

  1. APPENDIX 1: TABULATED DATA

 

  1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Presently, close to 50 companies are offering a variety of analytical testing solutions for the assessment of novel cancer biomarkers; majority of these tests are intended to facilitate important therapy-related decisions, claims Roots Analysis


Submitted 92 day(s) ago by Harry sins

 

 

Over time, pharmaceutical players have demonstrated significant interest in this domain and have launched clinical research initiatives to investigate the relevance and applications of these novel biomarkers. Several companies have already developed / are developing analytical tests for novel cancer biomarkers (TMB, MSI / MMR and TILs), intended to assist physicians in making personalized treatment decisions.

 

To order this 370+ page report, which features 190+ figures and 180+ tables, please visit this link

 

The USD  860 million (by 2030) financial opportunity within the cancer biomarkers market has been analyzed across the following segments:

  • Type of test
  • Laboratory Developed Tests (LDTs)
  • Companion Diagnostic Tests (CDx)

 

  • Type of disease indication
  • Breast cancer
  • Blood cancer
  • Colon / Colorectal cancer
  • Lung Cancer
  • Melanoma
  • Prostate Cancer

 

  • Type of cancer biomarker
  • TMB
  • MSI / MMR
  • TILs

 

  • Type of analytical technique
  • Next Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Others

 

  • Key geographical regions
  • North America
  • Europe
  • Japan
  • China
  • Australia

 

The Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030 report features the following companies, which we identified to be key players in this domain:

  • Foundation Medicine
  • NeoGenomics Laboratories
  • Novogene
  • Q2 Solutions
  • Personal Genome Diagnostics
  • Dr Lal PathLabs
  • Shenzhen Yuce Biotechnology

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Current Market Landscape

  4. Product Competitiveness Analysis

  5. Company Profiles

  6. Publication Analysis

  7. Innovative Designs for Biomarker-Based Clinical Trials

  8. Clinical Trial Analysis

  9. Market Forecast

  10. Future Growth Opportunities

  11. Case Study: Analysis of Needs of Stakeholders in The Companion Diagnostics Industry

  12. Case Study: Analysis of Value Chain in the Companion Diagnostics Industry

  13. Clinical Research on Cancer Biomarkers: A Big Pharma Perspective

 

  1. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com 

 

 

Cancer biomarkers market for TMB, MSI / MMR and TILs is projected to grow at an annualized rate of ~18%, till 2030


Submitted 92 day(s) ago by Harry sins

 

Roots Analysis has done a detailed study on Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030, covering key aspects of the industry and identifying key future growth opportunities.

 

To order this 370+ page report, which features 190+ figures and 180+ tables, please visit this link

 

Key Market Insights

  • Several novel biomarkers are presently under investigation for a variety of cancer indications; the initiatives of big pharmaceutical companies are indicative of the growing interest in this domain
  • Presently, close to 50 companies are offering a variety of analytical testing solutions for the assessment of novel cancer biomarkers; majority of these tests are intended to facilitate important therapy-related decisions
  • Multiple tests are currently available for specific diseases indications; next generation sequencing has emerged as a key driver, enabling high throughput results and faster turnaround times
  • Companies involved in this domain are putting in significant efforts to develop efficient tests and differentiate their offerings, from those of other stakeholders, to maintain a competitive edge
  • Till date, close to 200 trials, evaluating the expression of novel biomarkers have been registered across different cancer indications, phases of development and geographical locations
  • The growing research activity in this domain is also evident across published scientific literature; several biomarker-focused studies are evaluating different types of immunotherapies
  • The growing interest in this field is also reflected by the 120+ partnerships have been signed in the last two years, involving both international and indigenous stakeholders
  • The opportunity is likely to be driven by the applicability of these tests across multiple cancer indications; the market is anticipated to grow as more biomarker based drugs get approved in the coming decade
  • The projected future opportunity is expected to be distributed across different application areas, types of analytical techniques used and various global regions

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html

 

Table of Contents

 

  1. PREFACE

1.1.      Scope of the Report

1.2.      Research Methodology

1.3.      Chapter Outlines

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.      Chapter Overview

3.2.      Cancer Immunotherapy

3.2.1.    Cancer Immunotherapy Biomarkers

3.2.2.    Identification of a Candidate Biomarker

3.2.3.    Need for Novel Cancer Biomarkers

 

3.3.      Tumor Mutation Burden (TMB)

3.3.1.    Overview

3.3.2.    Variation of TMB across Multiple Indications

3.3.3.    Methods for Measurement of TMB

3.3.4.    Factors Affecting Measurement of TMB

3.3.5.    Initiatives for Assessment of TMB as a Potential Biomarker

 

3.4.      Microsatellite Instability / Mismatch Repair Deficiency (MSI / MMR)

3.4.1.    Overview

3.4.2.    Variation of MSI across Multiple Indications

3.4.3.    Methods of Measurement of MSI

 

3.5.      Tumor Infiltrating Lymphocytes and Other Novel Biomarkers

 

4          CURRENT MARKET LANDSCAPE

4.1.      Chapter Overview

4.2.      Cancer Biomarkers Testing Services: Overall Market Landscape

4.2.1.    Analysis by Year of Establishment

4.2.2.    Analysis by Company Size

4.2.3.    Analysis by Geographical Location

4.2.4.    Analysis by Test Availability

4.2.5.    Analysis by Type of Biomarker

4.2.6.    Analysis by Application Area

4.2.7.    Analysis by Disease Indication

4.2.8.    Analysis by Analytical Technique Used

4.2.9.    Analysis by Turnaround Time

4.2.10.  Analysis by Sample Input

4.2.11.  Analysis by Nucleic Acid Tested

4.2.12.  Key Players: Analysis by Type of Biomarker

 

4.3.      TMB Tests

4.3.1.    Analysis by Application Area

4.3.2.    Analysis by Disease Indication

4.3.3.    Analysis by Analytical Technique Used

4.3.4.    Analysis by Turnaround Time

 

4.4.      MSI / MMR Tests

4.4.1.    Analysis by Application Area

4.4.2.    Analysis by Disease Indication

4.4.3.    Analysis by Analytical Technique Used

4.4.4.    Analysis by Turnaround Time

 

4.5.      TIL-based Tests

4.5.1.    Analysis by Application Area

4.5.2.    Analysis by Disease Indication

4.5.3.    Analysis by Analytical Technique Used

4.5.4.    Analysis by Turnaround Time

 

5          PRODUCT COMPETITIVENESS ANALYSIS

5.1.      Chapter Overview

5.2.      Product Competitiveness Analysis: Key Assumptions and Methodology

5.2.1.    Tests for the Assessment of TMB

5.2.2.    Tests for the Assessment of MSI / MMR

5.2.3.    Tests for the Assessment of TILs

 

6          COMPANY PROFILES

6.1.      Chapter Overview

6.2.      Dr Lal PathLabs

6.2.1.    Company Overview      

6.2.2.    Financial Information    

6.2.3.    Product / Service Portfolio        

6.2.3.1. Biomarkers Testing Portfolio     

6.2.3.1.1. Microsatellite Instability (MSI) by PCR

6.2.3.1.2. OncoPro NCCN Lung Cancer Panel (*9 Genes *MSI)  

6.2.3.1.3. OncoPro Liquid Biopsy 73 Gene Panel with MSI         

6.2.4.    Recent Developments and Future Outlook         

 

6.3.      Foundation Medicine    

6.3.1.    Company Overview      

6.3.2.    Financial Information    

6.3.3.    Product / Service Portfolio        

6.3.3.1. Biomarkers Testing Portfolio     

6.3.3.1.1. FoundationOne CDx  

6.3.3.1.2. FoundationOne Liquid

6.3.3.1.3. FoundationOne Heme

6.3.4.    Recent Developments and Future Outlook         

           

6.4.      NeoGenomics Laboratories      

6.4.1.    Company Overview      

6.4.2.    Financial Information    

6.4.3.    Product / Service Portfolio        

6.4.3.1. Biomarkers Testing Portfolio     

6.4.3.1.1. NeoTYPE Discovery Profile for Solid Tumors  

6.4.3.1.2. MSI Analysis / MMR Panel by IHC      

6.4.3.1.3. MultiOmyx Tumor Infiltrating Lymphocyte Panel          

6.4.4.    Recent Developments and Future Outlook         

 

6.5.      Novogene        

6.5.1.    Company Overview      

6.5.2.    Product / Service Portfolio        

6.5.2.1. Biomarkers Testing Portfolio     

6.5.2.1.1. NovoPM Cancer Panel          

6.5.2.1.2. NovoPM TMB

6.5.2.1.3. NovoPM bTMB

6.5.2.1.4. NovoPM MSI

6.5.3.    Recent Developments and Future Outlook

 

6.6.      Q2 Solutions    

6.6.1.    Company Overview      

6.6.2.    Product / Service Portfolio        

6.6.2.1. Biomarkers Testing Portfolio     

6.6.2.1.1. TMB Assay   

6.6.2.1.2. MSI Assay    

6.6.2.1.3. TILs Testing 

6.6.3.    Recent Developments and Future Outlook

           

6.7.      Personal Genome Diagnostics 

6.7.1.    Company Overview      

6.7.2.    Product / Service Portfolio        

6.7.2.1. Biomarkers Testing Portfolio     

6.7.2.1.1. PGDx elio Tissue Complete Assay     

6.7.2.1.2. PlasmaSELECT-R 64

6.7.2.1.3. CancerXOME-R        

6.7.2.1.4. CancerSELECT-R 125           

6.7.2.1.5. MutatorDETECT       

6.7.3.    Recent Developments and Future Outlook         

 

6.8.      Shenzhen Yuce Biotechnology 

6.8.1.    Company Overview      

6.8.2.    Product / Service Portfolio        

6.8.2.1. Biomarkers Testing Portfolio     

6.8.2.1.1. YuceOne Plus           

6.8.2.1.2. YuceOne ICIs

6.8.2.1.3. ct-DNA TMB 

6.8.2.1.4. Microsatellite (MSI) Test        

6.8.3.    Recent Developments and Future Outlook

           

7          PUBLICATION ANALYSIS

7.1.      Chapter Overview

7.2.      Methodology

7.3.      Cancer Biomarkers: List of Publications

7.3.1.    Analysis by Year of Publication, 2016-2019

7.3.2.    Analysis by Year of Publication and Type of Biomarker

7.3.3.    Analysis by Year of Publication and Disease Indication

7.3.4.    Analysis by Year of Publication and Analytical Technique Used

7.3.5.    Analysis by Year of Publication and Type of Cancer Therapy

7.3.6.    Most Popular Journals

 

7.4.      Publication Analysis: TMB

7.4.1.    Analysis by Year of Publication, 2016-2019

7.4.2.    Analysis by Disease Indication

7.4.3.    Analysis by Analytical Technique Used

7.4.4.    Most Popular Journals

 

7.5.      Publication Analysis: MSI / MMR

7.5.1.    Analysis by Year of Publication, 2016-2019

7.5.2.    Analysis by Disease Indication

7.5.3.    Analysis by Analytical Technique Used

7.5.4.    Most Popular Journals

 

7.6.      Publication Analysis: TILs

7.6.1.    Analysis by Year of Publication, 2016-2019

7.6.2.    Analysis by Disease Indication

7.6.3.    Analysis by Analytical Technique Used

7.6.4.    Most Popular Journals

 

8          INNOVATIVE DESIGNS FOR BIOMARKER-BASED CLINICAL TRIALS

8.1.      Background and Context

8.2.      Biomarker-based Clinical Trial Designs

8.2.1.    Enrichment Design

8.2.2.    All-Comers Design

8.2.3.    Mixture / Hybrid Design

8.2.4.    Adaptive Design

8.3       Regulatory Considerations

 

9          CLINICAL TRIAL ANALYSIS

9.1.      Chapter Overview

9.2.      Methodology

9.3.      Cancer Biomarkers: List of Clinical Trials

9.4.      Clinical Trial Analysis: TMB

9.4.1.    Analysis by Trial Registration Year

9.4.2.    Analysis by Trial Recruitment Status

9.4.3.    Analysis by Trial Phase

9.4.4.    Analysis by Trial Design

9.4.5.    Analysis by Disease Indication

9.4.6.    Most Active Players

9.4.7.    Analysis by Number of Clinical Trials and Geography

9.4.8.    Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status

9.4.9.    Analysis by Enrolled Patient Population and Geography

9.4.10.  Analysis by Enrolled Patient Population, Trial Phase and Recruitment Status

 

9.5.      Clinical Trial Analysis: MSI / MMR

9.5.1.    Analysis by Trial Registration Year

9.5.2.    Analysis by Trial Recruitment Status

9.5.3.    Analysis by Trial Phase

9.5.4.    Analysis by Trial Design

9.5.5.    Analysis by Disease Indication

9.5.6.    Most Active Players

9.5.7.    Analysis by Number of Clinical Trials and Geography

9.5.8.    Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status

9.5.9.    Analysis by Enrolled Patient Population and Geography

9.5.10.  Analysis by Enrolled Patient Population, Trial Phase and Recruitment Status

 

9.6.      Clinical Trial Analysis: TILs

9.6.1.    Analysis by Trial Registration Year

9.6.2.    Analysis by Trial Recruitment Status

9.6.3.    Analysis by Trial Phase

9.6.4.    Analysis by Trial Design

9.6.5.    Analysis by Disease Indication

9.6.6.    Most Active Players

9.6.7.    Analysis by Number of Clinical Trials and Geography

9.6.8.    Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status

9.6.9.    Analysis by Enrolled Patient Population and Geography

9.6.10.  Analysis by Enrolled Patient Population, Trial Phase and Recruitment Status

 

9.7       Clinical Trials Summary: Analysis by Registration Year and Biomarker

9.8       Clinical Trials Summary: Analysis by Registration Year and Disease Indication

 

  1. MARKET FORECAST

10.1.     Chapter Overview

10.2.     Assumptions

10.3      Forecast Methodology

10.4.     Global Cancer Biomarkers Testing Market, 2019-2030 (By Value)

10.5.     Global Cancer Biomarkers Testing Market, 2019-2030 (By Volume)

10.6.     Cancer Biomarkers Testing Market: Distribution by Geography, 2019-2030 (By Value)

10.7.     Cancer Biomarkers Testing Market: Distribution by Geography, 2019-2030 (By Volume)

10.8.     Cancer Biomarkers Testing Market: Distribution by Type of Test, 2019-2030 (By Value)

10.8.1.  Cancer Biomarkers Testing Market: Distribution by Type of test and Geography, 2019-2030 (By Value)

10.9.     Cancer Biomarkers Testing Market: Distribution by Type of test, 2019-2030 (By Volume)

10.9.1.  Cancer Biomarkers Testing Market: Distribution by Type of test and Geography, 2019-2030 (By Volume)

10.10.   Cancer Biomarkers Testing Market: Distribution by Disease Indication, 2019-2030 (By Value)

10.11.   Cancer Biomarkers Testing Market:  Distribution by Disease Indication, 2019-2030 (By Volume)

10.12.   Cancer Biomarkers Testing Market:  Distribution by Analytical Technique, 2019-2030 (By Value)

10.12.1. Cancer Biomarkers Testing Market: Distribution by Analytical Technique and Geography, 2019-        2030 (By Value)

10.13.   Cancer Biomarkers Testing Market: Distribution by Analytical Technique, 2019-2030 (By Volume)

10.13.1. Cancer Biomarkers Testing Market: Distribution by Analytical Technique and Geography, 2019-2030 (By Volume)

10.14.   Cancer Biomarkers Testing Market: Distribution by Biomarker, 2019-2030 (By Value)

10.15.   Cancer Biomarkers Testing Market for TMB, 2019-2030 (By Value)

10.15.1. Cancer Biomarkers Testing Market for TMB: Distribution by Geography, 2019-2030 (By Value)

10.15.2. Cancer Biomarkers Testing Market for TMB: Distribution by Cancer Indication, 2019-2030 (By Value)

10.15.3. Cancer Biomarkers Testing Market for TMB: Distribution by Analytical Technique, 2019-2030 (By Value)

10.15.4. Cancer Biomarkers Testing Market for TMB: Distribution by Type of test, 2019-2030 (By Value)

10.16.   Cancer Biomarkers Testing Market for MSI / MMR, 2019-2030 (By Value)

10.16.1. Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Geography, 2019-2030 (By Value)

10.16.2. Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Cancer Indication, 2019-2030 (By Value)

10.16.3. Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Analytical Technique, 2019-2030 (By Value)

10.16.4. Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Type of test, 2019-2030 (By Value)

10.17.   Cancer Biomarkers Testing Market for TILs, 2019-2030 (By Value)

10.17.1. Cancer Biomarkers Testing Market for TILs: Distribution by Geography, 2019-2030 (By Value)

10.17.2. Cancer Biomarkers Testing Market for TILs: Distribution by Cancer Indication, 2019-2030 (By Value)

10.17.3. Cancer Biomarkers Testing Market for TILs: Distribution by Analytical Technique, 2019-2030 (By Value)

10.17.4. Cancer Biomarkers Testing Market for TILs: Distribution by Type of test, 2019-2030 (By Value)

10.18.   Cancer Biomarkers Testing Market: Distribution by Biomarker, 2019-2030 (By Volume)

10.19.   Cancer Biomarkers Testing Market for TMB, 2019-2030 (By Volume)

10.19.1. Cancer Biomarkers Testing Market for TMB: Distribution by Geography, 2019-2030 (By Volume)

10.19.2. Cancer Biomarkers Testing Market for TMB: Distribution by Cancer Indication, 2019-2030 (By Volume)

10.19.3. Cancer Biomarkers Testing Market for TMB: Distribution by Analytical Technique, 2019-2030 (By Volume)

10.19.4. Cancer Biomarkers Testing Market for TMB: Distribution by Type of test, 2019-2030 (By Volume)

10.20.   Cancer Biomarkers Testing Market for MSI / MMR, 2019-2030 (By Volume)

10.20.1. Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Geography, 2019-2030 (By Volume)

10.20.2. Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Cancer Indication, 2019-2030 (By Volume)

10.20.3. Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Analytical Technique, 2019-2030 (By Volume)

10.20.4. Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Type of test, 2019-2030 (By Volume)

10.21.   Cancer Biomarkers Testing Market for TILs, 2019-2030 (By Volume)

10.21.1. Cancer Biomarkers Testing Market for TILs: Distribution by Geography, 2019-2030 (By Volume)

10.21.2. Cancer Biomarkers Testing Market for TILs: Distribution by Cancer Indication, 2019-2030 (By Volume)

10.21.3. Cancer Biomarkers Testing Market for TILs: Distribution by Analytical Technique, 2019-2030 (By Value)

10.21.4. Cancer Biomarkers Testing Market for TILs: Distribution by Type of Test, 2019-2030 (By Value)

 

  1. FUTURE GROWTH OPPORTUNITIES

11.1.     Chapter Overview

11.1.1.  Increasing Focus on Precision Medicine

11.1.2.  Rise in Number of Biomarker-based Clinical Trials

11.1.3.  Emerging Technologies for Biomarker Assessment

11.1.4.  Development of Companion Diagnostic Products

11.1.5.  Other Opportunities

 

  1. CASE STUDY: ANALYSIS OF NEEDS OF STAKEHOLDERS IN THE COMPANION DIAGNOSTICS INDUSTRY

12.1.     Chapter Overview

12.2.     Companion Diagnostics: Needs of Different Stakeholders

12.3.     Comparison of Needs of Various Stakeholders

12.3.1.  Needs of Drug Developers

12.3.2.  Needs of Companion Diagnostics Developers

12.3.3.  Needs of Regulatory Authorities

12.3.4.  Needs of Testing Laboratories

12.3.5.  Needs of Payers / Insurance Providers

12.3.6.  Needs of Physicians

12.3.7.  Needs of Patients

 

  1. CASE STUDY: ANALYSIS OF VALUE CHAIN IN THE COMPANION DIAGNOSTICS INDUSTRY

13.1.     Chapter Overview

13.2.     Companion Diagnostics: Components of the Value Chain

13.3.     Companion Diagnostics Value Chain: Cost Distribution

13.3.1.  Companion Diagnostics Value Chain: Costs Associated with Research and Product Development

13.3.2.  Companion Diagnostics Value Chain: Costs Associated with Costs Associated with Manufacturing and Assembly

13.3.3.  Companion Diagnostics Value Chain: Costs Associated with Clinical Trials, FDA Approval and Other Administrative Tasks

13.3.4.  Companion Diagnostics Value Chain: Costs Associated with Payer Negotiation and KoL Engagement

13.3.5.  Companion Diagnostics Value Chain: Costs Associated with Marketing and Sales

 

  1. CLINICAL RESEARCH ON CANCER BIOMARKERS: A BIG PHARMA PERSPECTIVE

14.1.     Chapter Overview

14.2.     Methodology

14.3.     Clinical Trial Analysis

14.3.1.  List of Likely Drug Candidates for IVD Developers

14.4.     Cumulative Distribution of Biomarker-based Trials by Registration Year, 2016-2019

14.4.1.  Analysis of Biomarker-based Trials of Most Popular Biomarkers

14.4.2.  Analysis of Biomarker-based Trials of Moderately Popular Biomarkers

14.4.3.  Analysis of Biomarker-based Trials of Less Popular / Other Biomarkers

14.4.4.  Word Cloud of Other Emerging Biomarkers

 

14.4.5.  Cumulative Distribution of Trials by Registration year and Most Popular Biomarkers

14.4.6.  Cumulative Distribution of Trials by Registration year and Moderately Popular Biomarkers

14.4.7.  Cumulative Distribution of Trials by Registration year and Less Popular / Other Biomarkers

14.5.     Distribution of Biomarker-based Trials by Most Popular Indications

14.5.1.  Distribution of Biomarker-based Trials by Moderately Popular Indications

14.5.2.  Distribution of Biomarker-based Trials by Less Popular / Other Indications

14.5.3.  Word Cloud of Other Emerging Indications in Biomarker-based Clinical Trials

14.5.4.  Cumulative Distribution of Trials by Registration year and Most Popular Indication

14.5.5.  Cumulative Distribution of Trials by Registration year and Moderately Popular Indications

14.5.6.  Cumulative Distribution of Trials by Registration year and Less Popular / Other Indications

14.6.     Analysis of Biomarker-based Trials by Phase of Development

14.6.1.  Analysis of Biomarker-based Trials by Phase of Development and Most Popular Biomarkers

14.6.2.  Analysis of Biomarker-based Trials by Phase of Development and Moderately Popular Biomarkers

14.6.3.  Analysis of Biomarker-based Trials by Phase of Development and Less Popular and Other Biomarkers

14.6.4.  Analysis of Biomarker-based Trials by Phase of Development and Most Popular Indications

14.6.5.  Analysis of Biomarker-based Trials by Phase of Development and Moderately Popular Indications

14.6.6.  Analysis of Biomarker-based Trials by Phase of Development and Less Popular and Other Indications

14.7.     Analysis of Biomarker-based Trials by Sponsor

14.7.1.  Analysis of Biomarker-based Trials by Sponsor and Most Popular Biomarkers

14.7.2.  Analysis of Biomarker-based Trials by Sponsor and Moderately Popular Biomarkers

14.7.3.  Analysis of Biomarker-based Trials by Sponsor and Most Popular Indications

14.7.4.  Analysis of Biomarker-based Trials by Sponsor and Moderately Popular Indications

14.8.     Analysis of Biomarker-based Trials by Recruitment Status

14.9.     Analysis of Biomarker-based Trials by Therapy Design

14.10.   Analysis of Biomarker-based Trials by Geography

14.10.1. Analysis of Biomarker-based Trials by Trial Phase and Recruitment Status

14.11.   Clinical Trials Summary: Analysis by Biomarker and Most Popular Indications

14.12.   Clinical Trials Summary: Analysis by Biomarker and Moderately Popular Indications

14.13.   Clinical Trials Summary: Analysis by Biomarker and Other Emerging Indications

  1. EXECUTIVE INSIGHTS
  2. APPENDIX 1: TABULATED DATA
  3. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

Watch UFC 254 live free from anywhere – MMA Streams Free Reddit

www.streetinsider.com
Submitted 132 day(s) ago by nowkala24

Watch UFC 254 live free from anywhere – MMA Streams Free Reddit

UFC 252: Stipe Miocic Post-fight Press Conference - YouTube

www.youtube.com
Submitted 200 day(s) ago by system

Watch UFC heavyweight champion Stipe Miocic give his post-fight remarks after winning the trilogy fight with Daniel Cormier and successfully defending his ti...

Debate begins for who's first in line for COVID-19 vaccine | KOMO

komonews.com
Submitted 213 day(s) ago by system

(AP) — Who gets to be first in line for a COVID-19 vaccine? U. S. health authorities hope by late next month to have some draft guidance on how to ration initial doses, but it’s a vexing decision. “Not everybody’s going to like the answer,” Dr. Francis Collins, director of the National Institutes of Health, recently told one of the advisory groups the government asked to help decide. “There will be many people who feel that they should have been at the top of the list. ”

Dell XPS 13, XPS 15 2020 Model May Be Launched in India on July 8, Amazon Listing Suggests | Technology News

gadgets.ndtv.com
Submitted 242 day(s) ago by system

Dell XPS 13 and XPS 15 slim and light laptops have been listed on Amazon India and will be launching soon. Though the Amazon page does not mention a launch date, the two laptops may arrive in India on July 8, as the company has sent out invites for a digital event on Wednesday where it will unveil “The XPS Experience”.

Church tied to Oregon's largest coronavirus outbreak | KBOI

idahonews.com
Submitted 258 day(s) ago by system

SALEM, Ore. (AP) - A church in rural northeastern Oregon is now the epicenter of the state's largest coronavirus outbreak, as 236 people tested positive for the disease, authorities said Tuesday. The outbreak also led to Oregon's second consecutive record-setting daily case count. "I think generally we are seeing increasing numbers, which is what we expected with reopening," said Thomas Jeanne, the deputy state health officer and deputy state epidemiologist.

YouTube

www.youtube.com
Submitted 262 day(s) ago by system

Maria Ressa, the head of Philippines news website Rappler, known for critical reports about president Rodrigo Duterte, has been found guilty of 'cyber libel'...

Scientists Press Mammal 'Snooze Button' to Understand Hibernation | Technology News

gadgets.ndtv.com
Submitted 265 day(s) ago by system

Could humans eventually be induced to hibernate to protect them after an injury or preserve them during deep space travel?

Cuomo declares "exciting new phase" for New York as coronavirus cases continue to decline - CBS News

www.cbsnews.com
Submitted 296 day(s) ago by system

On Sunday, Cuomo announced that hospitalizations, intubations and new cases of coronavirus are all down.

Samsung Galaxy M21 Specifications, Renders Leaked Ahead of Launch | Technology News

gadgets.ndtv.com
Submitted 352 day(s) ago by system

Samsung Galaxy M21's specifications and press renders have been leaked in a fresh report ahead of its Wednesday launch.

Fabio Wajngarten, Brazilian president's press secretary, tests positive for coronavirus. - CNN

edition.cnn.com
Submitted 356 day(s) ago by system

Fabio Wajngarten, the press secretary for Brazilian President Jair Bolsonaro, tested positive for coronavirus on Thursday, two sources have told CNN. Bolsonaro's health is being monitored.

Submit your article?

Submit your articles for more traffic to your website!

Submit
© 2019 posts123.com. Imprint, All rights reserved.